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Viral infection of host cells induces the Type I interferon (IFN) response, which is 
characterized by the production of hundreds of IFN-stimulated genes (ISGs). Altogether, these 
ISGs function to induce an antiviral state, hindering or blocking various steps of the viral 
lifecycle. Many individual ISGs have potent and broad antiviral functions. However elimination 
of a single ISG does not completely abrogate protection, suggesting that other ISGs, although 
moderate or moderate when considered alone, must work cooperatively to provide optimal 
antiviral activity.  
In order to identify and characterize novel ISGs, an attenuated strain of the alphavirus 
chikungunya (CHIKV-181/25) was tested against an shRNA library of 243 curated murine genes 
upregulated during IFN treatment. An attenuated CHIKV strain was used with the assumption 
that ISGs with moderate or low activity may be more easily identified due to the reduced 
pathogenicity of the virus. In addition, the orthobunyavirus LaCrosse (LACV) was also tested, as 
	  	   vi	  
there have been no large scale ISG screens using this pathogen. A total of 21 and 30 novel 
murine ISGs that putatively restrict infection were identified from the CHIKV-181/25 screen and 
the LACV screen, respectively.  
Although independent confirmation of many candidate antiviral ISG targets using bulk 
CRISPR lines is still ongoing, we were able to validate and characterize the antiviral role of one 
of these targets, IFITM3, against alphaviruses in vitro and in vivo. Alphaviruses, which were 
previously thought to be unaffected by this ISG, exhibit reduced replication due to restriction by 
Ifitm3 at the endosomal fusion stage of infection. Ifitm3-/- mice infected with CHIKV exhibited 
greater swelling of the ipsilateral foot at peak days of pathology. Higher viral titers in the spleen, 
serum and ipsilateral foot were seen at 1 day after infection, coinciding with increased cytokines 
and chemokines in the ipsilateral foot. Splenic macrophages from Ifitm3-/- mice exhibited greater 
levels of viral antigen at 1 day after infection with CHIKV, and cultured bone marrow derived 
macrophages lacking Ifitm3 supported enhanced CHIKV replication. To test whether Ifitm3 
restricts encephalitic alphaviruses we infected WT and Ifitm3-/- mice with VEEV-TC83-A3G, 
and observed increased mortality and viral burden in Ifitm3-/- animals. 
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Chapter 1: Introduction 
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THE INNATE IMMUNE RESPONSE TO VIRAL INFECTION 
The innate immune system allows for the rapid identification and response to infection in 
an antigen-independent manner. Through pattern recognition receptors (PRRs), host cells can 
detect a wide variety of pathogen-associated molecular patterns (PAMPs). PRRs are found on the 
surface, in endosomes, and the cytosol of host cells, and are activated by PAMPs unique to 
bacteria, fungi, parasites, or viruses. In the case of viral infection, there are several PRRs which 
can identify viral or foreign nucleic acids (1). The RIG-I like receptors (RIG-I and MDA-5) 
recognize viral single-stranded (ssRNA) and double-stranded RNA (dsRNA) in the cytoplasm, 
while cGAS/STING, IFI16 and DAI detect cytosolic DNA (2). Nucleic acids in the endosome 
are recognized by the Toll-like receptors TLR3 (ds RNA), TLR7 (ssRNA), and TLR9 (dsDNA) 
(3). Upon detection of viral nucleic acids, signaling cascades are initiated to activate the 
transcription factors IRF3, IRF7 and NF-kB. These transcription factors induce the production of 
pro-inflammatory cytokines and Type I and III Interferons (IFN) (2). 
 
TYPE I, II AND III IFN 
Type I IFNs were first described in 1957 (4). They include IFNα (of which there are 12 
subtypes), IFNβ, and a series of other poorly defined cytokines such as IFNε, IFNκ and IFNω 
(2). Once secreted, IFN functions in an autocrine and paracrine manner, binding to the Type I 
Interferon receptor (IFNAR), a heterodimer which is expressed transiently on most host cells. 
This initiates a signal cascade through the JAK/STAT pathway, through which STAT1/STAT2 
heterodimers bind to IRF9 and form the IFN-stimulated gene factor 3 (ISGF3) complex. ISGF3 
binds to promoters containing IFN stimulated response elements (ISREs) (2), activating the 
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transcription of hundreds of genes (2). These genes, classified as Interferon Stimulated Genes 
(ISGs), function to restrict pathogenesis at the different steps of the viral replication cycle, thus 
inducing a rapid and broad antiviral state in both infected and local naïve host cells.  
In addition to Type I IFN, Type III IFN (IFNλ1, IFNλ2, IFNλ3 and IFNλ4) can also be 
induced via the detection of viral PAMPs (2, 5), and can promote the induction of ISRE activated 
ISGs via the IFNλ receptor, albeit not as potently as Type I. However, the expression of the IFNλ 
receptor is restricted to epithelial cells and some immune cells, leaving most cells in the host 
unresponsive to Type III IFNs (2, 5). 
Type II IFN, consisting only of IFNγ, is not transduced via the direct detection of viral 
PAMPs, but rather through the detection of the pro-inflammatory cytokine IL-12. Furthermore, 
IFNγ is only produced in neutrophils, natural killer cells and T cells. IFNγ signals through the 
Type II IFN receptor (IFNGR), initiating the JAK/STAT pathway and inducing the transcription 
of pro-inflammatory and apoptotic genes linked to IFNγ activated site (GAS) promoter elements, 
some of which are also found in the ISGs induced by Type I IFN (6). 
 
INTERFERON STIMULATED GENES 
  In cell culture, the number of ISGs produced varies with the dosage, duration, type of 
IFN treatment and cell type tested. By microarray analysis, most cells upregulate between 200-
1000 unique ISGs (7). The most potently inhibitory ISGs identified thus far function against a 
broad spectrum of viruses (7). However, antiviral activity is still seen in mice with targeted 
deletions of these ISGs (8), suggesting that other ISGs have significant and unique restrictive 
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functions. It is believed that most ISGs function as weak to moderate inhibitors, and work in a 
concerted manner to restrict infection. 
ISGs preventing entry: IFITMs, which were the first family of antiviral ISGs 
discovered, appear to prevent the entry via the endocytic pathway of a broad range of viruses, 
including influenza A virus (IAV) and flaviviruses (9). TRIM5α binds to the capsid proteins of 
retroviruses and accelerates uncoating of the virion (10). Mx is another potent ISG with antiviral 
properties against orthomyxoviruses, bunyaviruses, togaviruses and rhabdoviruses (2, 11). Mx 
proteins recognize and sequester viral nucleocapsids, preventing their transport to sites of 
genome amplification or egress. ADAP2 has recently been shown to restrict entry of DENV and 
VSV by altering endosomal uptake and intracellular trafficking (12).  
ISGs preventing viral translation and transcription: Upon recognition of viral dsRNA 
in the cytosol, 2'-5' oligoadenylate synthetase (OAS) activates RNAseL to initiate nucleic acid 
degradation (13). APOBECs and ADAR have been shown to directly edit viral RNA, resulting in 
nucleic acid destabilization and the introduction of lethal mutations. IFITs can block translation 
of viral RNA by binding to the eIF3 complex. They can also recognize the 5’-ppp motif on viral 
RNA, or the lack of the 2’-O methylation group normally found in eukaryotic RNA, and 
prevents translation by directly sequestering them (14). PKR is a prominent ISG, which 
functions by binding to viral RNA and blocking translation by phosphorylating (and inactivating) 
the translation initiation factor EIF2α (13). 
ISGs preventing viral protein function, assembly and egress: ISG15 is an ubiquitin 
like modifier that conjugates viral proteins in a process called ISGylation, thus affecting a 
plethora of viral protein functions (15–17). Viperin associates with endoplasmic reticulum, 
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interfering with the assembly of viral proteins and egress of virions at the plasma membrane 
(18). Finally, tetherin has been shown to prevent the release of viral particles from the plasma 
membrane (19). 
Proviral ISGs: ISGs have also been identified that induce an immunomodulatory 
response. In a high throughput screen, where ISGs were ectopically expressed in vitro, the ISGs 
ADAR, APOBEC3A, LY6E, MCOLN, IDO1, and FAM46C, increased replication of YFV, WNV, 
VEEV and CHIKV, though specific mechanisms are as of yet unclear (20). ASCC3 was 
identified as a proviral ISG in WNV infection, which dampens Type I IFN dependent signals, 
possibly through modulating IRF3 and IRF7 (21). Suppressor of cytokine signaling (SOCS) is 
produced early in the Type I IFN response and binds to the phosphorylated tyrosine residues of 
the IFN receptors or the JAK proteins, thus blocking JAK-STAT signaling (2).  USP18 is a 
potent down-regulator of the Type I IFN response. It binds to the intracellular domain of 
IFNAR2, altering its conformation and dramatically reducing the binding affinity of IFNα to the 
receptor (22). 
 
PRIOR SCREENS TO IDENTIFY AND CHARACTERIZE NOVEL ISGS  
The antiviral functions of many ISGs are largely unknown. Small-scale studies identified 
a few key ISGs involved in the restriction of certain viruses. For example, an siRNA screen 
against influenza A identified IFITM3 as a potent antiviral ISG, and was subsequently confirmed 
to restrict WNV and dengue virus (9). The first large scale ectopic expression screen was 
published in 2011.  In this study,  a lentiviral library expressing 380 human ISGs was used to 
determine restriction of six different viruses (Hepatitis C Virus (HCV), Human 
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Immunodeficiency Virus (HIV), YFV, WNV, VEEV, and CHIKV) (20). This ectopic expression 
based analysis identified ISGs that act broadly, or to only one virus. Most ISGs identified had 
moderate antiviral activity, and acted as inhibitors of translation. Expression of two different 
ISGs led to greater restriction of virus replication (20), confirming the notion that IFN based 
protection requires the additive effect of multiple ISGs. 
Another group developed a large-scale screen to identify novel ISGs against WNV (21) 
by silencing gene targets using a lentiviral shRNA library against 245 human ISGs (23). This 
allowed investigation of the physiological role of each ISG in the context of an IFN-induced 
antiviral state. This approach could potentially identify ISGs that required a multicomponent 
complex to function. The screen against WNV identified 30 ISGs, of which 9 had not been 
previously identified to have any antiviral effect. 
Other groups have performed genome wide siRNA based screens to identify novel ISGs 
in vitro against VSV, MHV-68, and HCV (24–26). An in vivo RNA interference screen was 
developed in which mice were infected with a library of Sindbis viruses (SINV) encoding 
artificial microRNA (amiRNAs) against murine ORFs. Virions with amiRNAs targeting 
inhibitory genes were selected for, and the transcription factors like Zfx and Mga were identified 
(27). 
Recently a library of human and macaque ISGs were screened against eleven different 
retroviruses (28). Of the top antiviral ISGs discovered, around 60% targeted against a single 
retrovirus, while the remaining 40% were broadly effective. In addition, they also uncovered 
ISGs that functioned in a species specific manner. For example, human but not macaque 
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ANGTPL1 inhibited SIV infection. They go on to show that IDO1 (which was identified in a 
previous screen as proviral for other viruses (20)) and TRIM56 inhibit retroviral replication. 	  
 
ALPHAVIRUSES 
Alphaviruses are enveloped positive-sense ssRNA mosquito-borne viruses of the 
Togaviridae family and can be grouped as arthritogenic or encephalitic based on clinical 
symptoms. Arthritogenic alphaviruses present with severe polyarthralgia and polyarthritis while 
the encephalitic alphaviruses produce a severe febrile illness associated with infection and injury 
to neurons, encephalitis, long-term debilitating neurological sequelae, and death. Arthritogenic 
alphaviruses include CHIKV, Sindbis virus, O’Nyong-nyong virus, Ross River virus, Mayaro 
virus, and Semliki Forest virus and the encephalitic alphaviruses, including Venezuelan (VEEV), 
Eastern, and Western equine encephalitis viruses. 
 
CHIKUNGUNYA VIRUS 
CHIKV was originally isolated in 1952 in Tanzania, and has since cause explosive 
outbreaks worldwide. In fact, its name was derived from the Makonde word meaning “that which 
bends up”, alluding to the changes in posture and joint inflammation of patients suffering from 
the arthritic symptoms of infection (29).  
Typically, patients infected with CHIKV develop a severe febrile illness marked by 
polyarthritis, headache, conjunctivitis, and rash that can progress to persistent arthritis that can 
	  	   8	  
last for years after infection. CHIKV has become a growing concern since it emerged in the 
Caribbean in 2013 and subsequent spread to Central, South and North America, resulting in over 
1.8 million cases (30). Currently, there are no approved therapies or vaccines to combat or 
prevent CHIKV infection. 
CHIKV enters host cells via clatherin-mediated endocytosis, and fuses with the 
endosome in a pH-dependent manner. Replication of genomic RNA and translation of capsid 
protein occurs in the cytoplasm, which assemble into nucleocapsid cores. The E1 and E2 
glycoproteins are translated in the endoplasmic reticulum, and further processed in the Golgi, 
before going to the plasma membrane. Nucleocapsid cores assemble with the surface 
glycoproteins at the plasma membrane, leading to budding of mature virions (31). 
There are two mouse models of infection, the neonate model which can be used to 
determine viral dissemination and lethality, and the adult model which is used to better 
understand the acute symptoms and persistence of CHIKV-induced arthritis (32–34). In wild 
type mice as young as 4 weeks old, a biphasic pattern of swelling is observed in the inoculated 
foot. The first, small peak of swelling is seen at day 2 or 3 post infection, and is believed to be 
the result of viral replication in the fibroblasts, myocytes and osteoblasts, causing cell death, 
cytokine production and edema. The second, more prominent peak of swelling occurs at day 6-7 
post infection, which is largely due to infiltration of immune cells and the subsequent induction 
of edema, myositis and synovitis. Swelling rapidly drops to near normal levels soon after. 
Infectious CHIKV can be isolated from the serum, spleen, muscles, liver and ankle joints as early 
as 1 day post infection, but is rapidly cleared and typically undetectable by 5 to 7 days post 
infection. However, CHIKV RNA can be detected in the spleen for up to 42 days post infection, 
and in the joints for essentially the life of the animal (35–37). In addition, studies have shown 
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that osteoblast infection induces increased osteoclast production in the joints, resulting in 
possible bone loss (38, 39). 
CHIKV-181/25 (TSI-GSD-218) is an attenuated strain developed by the US Army 
through 18 serial passages of the parental CHIKV 15561 strain (40). While CHIKV-181/25 is 
immunogenic and protective, 8% of recipients developed chronic joint inflammation (41), and in 
at least one case symptoms were linked to a genetic reversion of the virus, thus preventing its use 
as an effective vaccine. The attenuated phenotype is mapped to two mutations in the E2 protein, 
which disturbs the binding of the virion to heparan sulfate on the cell surface. This reduction in 
binding affinity reduces the efficiency of infection, and also in turn affects cell spread and 
tropism in vivo (42). CHIKV-181/25 does not cause weight loss or death in WT, or in IFNγR-/- 
mice, and reduced morbidity in IFNAR-/- mice. Stat1-/- mice and IFNαβγ receptor knockout mice 
both suffer significant weight loss and mortality. Combined with evidence that IFNAR+/- mice 
have reduced morbidity than IFNAR-/- mice, it can be inferred that CHIKV-181/25 is susceptible 
to Type II and Type I IFN responses (43, 44). 
 
IDENTIFIED ISGS AGAINST ALPHAVIRUSES 
There are several studies characterizing the effect of ISGs against alphavirus infection. 
ISG15 protects against SINV in vivo, likely via conjugation (ISGylation) to viral proteins (15–
17). Zinc finger antiviral protein (ZAP) restricts SINV, Ross River, Semliki Forest, and VEEV 
by blocking the accumulation of viral genomic content in the cytoplasm (8). Tetherin has 
recently been shown to prevent egress by tethering virus onto the cell membrane (19), and ZAP 
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has been shown to work synergistically with 16 other ISGs to enhance restriction, including 
IFITM3 (45). 
In the absence of IFN, SINV is poorly restricted by RNaseL, and strongly inhibited by 
PKR in the context of replication in DCs (46). However, PKR-/- mice are still protected from 
lethal infection of SINV (8), suggesting that other ISGs can still confer protection. A genetic 
screen of SINV infected PKR/RNaseL double knockout mice revealed 44 unique ISGs with 
possible antiviral activity, including Isg20, Ifit1, Ifit2, Ifit3, and viperin (also shown to be 
restrictive against CHIKV) (47). However, in the case of Ifit1, which recognizes RNA lacking a 
2’O-methylation on the 5’cap structure and prevents translation, alphaviruses subvert this 
antiviral function via RNA secondary structure motifs that inhibit binding (48). Other ISGs like 
HSPE and P2RY6 have been identified, though their mechanisms of restriction are currently 
unknown (7, 20). 
 
LACROSSE VIRUS 
LaCrosse (LACV) is an enveloped negative-sense ssRNA orthobunyavirus with a 
segmented genome. This arthropod-borne virus is endemic to the United States (27, 28), and 
typically causes disease in children.  While most cases are asymptomatic or manifest in febrile 
illness, a small percentage of children develop seizures, chronic epilepsy, or fatal encephalitis 
(29). 
The replication cycle of bunyaviruses begins upon entry into host cells by clathrin-
mediated endocytosis. After pH-dependent fusion with the endosomal membrane and entry into 
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the cytosol, the encapsidated viral RNA genome segments undergo transcription by viral RNA 
dependent RNA polymerase (RdRp) to generate mRNA. The mRNA is then used to transcribe 
structural and nonstructural viral proteins. Structural proteins Gc and Gn dimerize in the ER and 
are transported to the Golgi. Meanwhile, RdRp generates positive strand antigenomic RNA, 
which is then used as a template to replicate more genomic copies. Ribonucleoproteins are 
generated in viral ‘factories’ and then transported to the Golgi for assembly. Virions are secreted 
via vesicles to the plasma membrane (30). LACV and other orthobunyaviruses can antagonize 
IFN production responses, particularly through the nonstructural protein NSs, which directly 
suppresses IFN induction (31). Mice infected with LACV succumb to neurological disease in a 
dose and age-dependent manner. This is believed to be due to differences in Type I IFN 
production. Older mice have more myeloid DCs present, which produce more Type I IFN via 
RLR and TLR3 activation (32). Selectively removing myeloid DCs from older mice increased 
susceptibility to LACV mediated neurological disease (32). 
A few well-known, strongly antiviral genes have been reported to restrict Bunyaviridae 
family members. Bunyaviruses like LACV and Rift Valley Fever Virus (RVFV) are strongly 
restricted by MxA, a highly conserved GTPase that prevents virus components from trafficking 
from the cytosol to the nucleus (33). MxA is potent enough to protect IFNAR-/- mice from a 
lethal dose of Thogoto virus (tick borne orthobunyavirus) and enhance resistance against LACV 
(34). Viperin (blocks egress), MTAP44 (aggregates microtubules; antiviral function unknown) 
and PKR (blocks translation) restrict infection by Bunyamwera Virus (35). IFITM2 and IFITM3 
were found to restrict RVFV in cell culture, by blocking viral fusion with the endosomal 
membrane, while IFITM1 had no discernable effect (36). Recent studies have shown that 
Oropouche and LACV are restricted by Irf3, Irf5 and Irf7 in the mouse, where the deletion of all 
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three genes leads to increased viral replication in the liver and spleen, and induces early 
mortality. Irf5 in particular was found to be required for control of viral replication in bone 
marrow derived DCs, faster infiltration of into the CNS and death (49, 50). In addition, both 
murine and human IFIT1 was found to have no discernable effect against Oropouche or LACV 
in vitro and in vivo (51). 
 
IFITM  
The interferon induced transmembrane (IFITM) family of proteins broadly restricts 
infection of several families of viruses. These proteins are expressed constitutively in most cell 
types, but also can be induced by type I, II and III IFNs (52). IFITMs are classified according to 
sequence similarity and function: Clade 1 contains IFITM1, 2 and 3 (and the mouse orthologs 6 
and 7), which participate in viral restriction; Clade 2 contains IFITM5, which is expressed in 
osteoblasts; and Clade 3 contains IFITM10, which is yet uncharacterized. Only IFITMs in Clade 
1 are IFN inducible (14, 52). 
Clade 1 IFITMs have 5 conserved domains (9, 52): the N terminal, the intramembrane, 
the conserved intracellular loop, the transmembrane, and the C terminal. IFITM2 and 3 contain a 
YXXΦ motif allowing for internalization into endosomes (53). IFITM1 lacks this motif and is 
believed to associate with the caveolin pathway. Further biochemical studies have identified key 
regions that affect IFITM function and localization. Lys124 in the N terminal domain is a site for 
ubiquitination (54), which mediates IFITM degradation. Palmitoylated cysteines in the 
intermembrane and transmembrane domains are necessary for localization and restriction of viral 
entry (54), and methylation of K88 appears to counter IFITMs antiviral capacity (55). The 
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orientation of IFITMs is largely unclear, and in the case of IFITM3, there are three prevailing 
models. However, the model with the most support has the N terminal domain in the intracellular 
region, and the C-terminal domain exposed to the extracellular space.  
IFITM proteins are basally expressed and localized primarily in late endosomes and 
lysosomes (52), co-localizing partially with LAMP2 and CD63 (56, 57). In addition, IFITM3 
associates with lipid rafts on the plasma membrane (58), and is expressed on the apical 
membrane and cilia of columnar epithelial cells of the airway (59). IFITM1 appears to co-
localize to subcellular compartments separate from IFITM2 and IFITM3 (60, 61). Ectopic 
expression of IFITMs results in increased expression on the plasma membrane surface. 
Furthermore, IFITM1 ectopic expressing cells have larger, empty vesicles, and IFITM3 cells 
develop multivesicular bodies (62). 
Antiviral activity of IFITMs was first observed against VSV (52), where infection was 
restricted in IFITM1 over-expressing cells. IFITM3 was later found to restrict influenza A by 
blocking entry at the hemifusion stage (9) in the late endosome, and also is protective in vivo (59, 
63). Since then, the effectiveness of IFITM restriction has been tested in vitro against many 
viruses (64). IFITM genes reportedly restrict infection of flaviviruses (WNV, DENV, ZIKV and 
JEV), HCV, filoviruses (EBOV and MARV), SARS coronavirus, bunyaviruses (RVFV, LACV), 
HIV, RSV and reoviruses (56, 60, 61, 64–71). IFITM3 has been shown to prevent HIV-1 
infection by incorporating directly into the virion, as well as preventing viral fusion and cell-to-
cell spread (72). In addition, HIV-1 has been shown to gain sensitivity to IFITM mediated 
restriction as the virus population develops mutations on the envelope glycoprotein to evade host 
neutralizing antibodies (73–75).  
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IFITMs reportedly do not have significant antiviral activity against Moloney Murine 
Leukemia Virus (retrovirus), Crimean–Congo Hemorrhagic Fever (CCHFV, a bunyavirus), and 
arenaviruses (9, 14, 20, 56, 60, 65). In addition, IFITMs do not restrict DNA viruses like Human 
Papilloma Virus (HPV), and Adenovirus (76), but may restrict Cytomegalovirus (CMV) and 
African Swine Fever virus (77). It is currently unknown why these viruses escape IFITM 
restriction, especially since many share common characteristics of entry as restricted ones. 
Correspondingly, the mechanism of protection by IFITMs also remains unclear. Over-expression 
of IFITMs has been shown to reduce membrane fluidity, increase cholesterol content and alter 
the curvature of endosomes, suggesting that IFITM physically alters the properties of the 
membrane to make viral fusion inefficient (78). For example, Amphotericin B, an antifungal that 
binds sterols in membranes, abrogates IFITM3 protection from influenza (79).  
The human polymorphism rs-12252 results in the deletion of the 21-nucleotide end of the 
N terminal of IFITM3. This deletion prevents localization to the endosome, restoring influenza 
(an observation that has been questioned in later publications (80, 81)) but not HIV infection 
(82). In addition, a recent publication with Hantaan virus suggests that the rs-12252 
polymorphism is responsible for increased disease severity and viral load in patients (83). These 
studies introduce the possibility that IFITM has more than one method of restriction. 
In this study, we use a library of murine ISG candidates to identify novel antiviral genes 
in a high throughput manner.  As most ISGs are believed to have a moderate to low potency, we 
decided to use an attenuated alphavirus (CHIKV-181/25) to try to identify novel targets that may 
be masked in the context of a more pathogenic strain. In addition, the orthobunyavirus LACV 
was also used, as this virus has not been previously used in large scale ISG screens. While the 
initial results still need to be independently verified, the screen identified the ISG Ifitm3. Though 
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Ifitm3 has been characterized as a potent and broad antiviral gene, alphaviruses were considered 
to be unaffected. Through in vitro and in vivo studies, we show that both arthritogenic and 
encephalitic alphaviruses are susceptible to Ifitm3 mediated restriction. 
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Chapter 2: Screening for novel antiviral ISGs against alphaviruses and orthobunyaviruses 
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ABSTRACT 
The identification and characterization of novel antiviral interferon-stimulated genes 
(ISGs) can help elucidate functions of viral replication and pathogenesis in vitro and in vivo. In 
addition, identifying novel mechanisms of restriction can provide new avenues of therapeutics 
for many viral diseases, including arboviruses like chikungunya and LaCrosse virus. Using a 
shRNA library targeting 243 unique ISG candidates, a total of 21 and 30 novel genes were 
determined to be antiviral against the attenuated strain CHIKV-181/25 and LACV, respectively. 
However, the efficacy of the screen was called into question, as only 1 of every 3 shRNA 
constructs against a particular gene was guaranteed to produce significant knockdown, and off-
target effects were never assessed. Independent assessment of the top hits against CHIKV-
181/25 using a transducible system to generate bulk CRISPR knockout cell lines has proven 
ineffective, and would require the generation of clonal lines before proper analysis can be done. 
Verification of certain target ISGs through readily available knockout cell lines and mouse 
models led us to identify Ifitm3 as having antiviral mechanisms against alphaviruses. 
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INTRODUCTION 
Of the hundreds to thousands of ISGs that are upregulated upon infection, the functions 
of only a small handful have been identified and further studied. An antiviral response is still 
seen in cell culture systems with the most potent ISGs removed, suggesting that the remaining 
uncharacterized ISGs have some protective functions. Most of these ISGs likely have mild to 
moderate antiviral activity on their own, and likely work synergistically to provide stronger 
restriction. Other ISGs may only be effective against a particular strain or family of viruses. 
Given the sheer number of ISGs, it is also likely that these genes have redundant functions, 
acting as a countermeasure against viruses that have evolved a means of avoiding restriction by 
other ISGs with a similar, but not exact mechanism of action. 
 Prior large scale screens for ISGs have focused on human targets (9, 20, 21, 24–26, 28, 
84), and used non-attenuated viruses. Although identifying novel antiviral human ISGs could 
direct a path toward targeted therapeutics, validation studies in animals would likely still be 
required. Some ISGs (like IFI6) identified from human screens against WNV did not have 
apparent mouse orthologs in part due to gene duplication and diversification, limiting their 
potential for further pathogenesis studies in vivo. Non–attenuated viruses may have the 
disadvantage of having mechanisms for antagonizing the function of specific ISGs or the IFN 
signaling response in general. In this case, moderate or weakly potent antiviral ISGs might be 
masked in a screen. Some attenuated or vaccine strains show impaired virulence due to their 
greater sensitivity to IFN, like WNV-Kunjin (85), making them a useful tool to reveal new 
antiviral ISGs. Furthermore, ISGs that are effective only against attenuated viruses can suggest 
novel viral immune evasion mechanisms. As an example, a virulent strain of WNV commonly 
used for pathogenesis studies exhibited no phenotype in IFIT1-/- mice or primary cells; the role of 
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IFIT1 as an antiviral effector was revealed with an attenuated genetic mutant virus that lacked 
2’-O methylation on its viral RNA (86, 87). 
 In this study, we employed a library of 756 unique shRNAs (targeting 243 unique murine 
ISGs) to screen against the attenuated alphavirus vaccine strain of chikungunya virus CHIKV-
181/25. In addition, we also used the library against the orthobunyavirus LACV, which has not 
been subject to a large, high-throughput ISG screen. As a segmented negative-stranded RNA 
virus, La Crosse is a unique encephalitic arbovirus and may thus be restricted by a distinct set of 
ISGs. By using a gene knockdown approach, this screen has the additional advantage of 
identifying antiviral ISGs in the context of physiological doses of IFN, and can be used to 
recognize ISGs that require a multi-component complex to function. From our initial screens, we 
identified 21 and 30 novel candidate antiviral ISGs against CHIKV-181/25 and LACV, 
respectively. While the results included ISGs of known antiviral function, providing evidence 
that the screen was successful, subsequent analysis of individual shRNAs against a particular 
gene target suggested that many of our results could be due to off-target effects. Independent 
assessment of select targets using bulk CRISPR lines has been so far incomplete, and further 
optimization of the system needs to be done. 
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MATERIALS AND METHODS 
Cells.  Vero, 293T, NIH 3T3 cells and MEFs were cultured in complete DMEM, which 
was supplemented with 10% fetal bovine serum, and 10 mM each of GlutaMAX, sodium 
pyruvate, non-essential amino acids and HEPES (pH 7.3). MEFs from β2mKbDb triple knockout 
mice were provided by Ken Murphy (Washington University in St Louis). 
Viruses. The CHIKV-181/25 strain was provided by the World Reference Center for 
Arboviruses (R. Tesh, University of Texas Medical Branch). The CHIKV-LR (La Reunion 
OPY1 p142) strain was a gift from S. Higgs (Kansas State University). LACV (original strain) 
was provided by Andrew Pekosz (Johns Hopkins University, Baltimore, MD) Virus propagation 
and titration was performed in Vero cells. 
Lentiviral packaging and transduction of shRNA. The shRNA library targeting 
murine ISGs was purchased commercially (Open Biosystems), and uses the lentiviral pGIPZ 
vector. This plasmid co-expresses shRNA and GFP downstream of the CMV promoter. 
Individual plasmids from the library were co-transfected in a 96 well format into 293T cells with 
the packaging plasmids pSPAX.2 and pMD2G using the FuGENE HD (Roche) transfection 
reagent, following manufacturer’s instructions. After 48 hours, lentiviral supernatants were 
harvested and transferred onto NIH-3T3 cells in a 96 well format with a final concentration of 
10ug/ml polybrene. Cells were spinoculated at 1000 x g at room temperature for 30 minutes 
before being placed in the 37°C incubator. Supernatant was replaced with complete DMEM 24 
hours later and returned to 37°C for 48 more hours to allow for efficient expression of GFP 
reporter and knockdown of the target genes.  
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ISG screening. The NIH-3T3 cells transduced with the lentiviral library for 72 hours 
were then treated with commercial mouse IFNβ (PBL) (2.5 IU/ml for CHIKV-181/25 or 1 IU/ml 
for LACV) for 6 hours, washed, and then infected with virus (MOI 5 of CHIKV-181/25 or MOI 
200 of LACV). These MOIs were chosen to facilitate 2-5% infection in the presence of IFN 
treatment or 70-80% infection in the absence of IFN treatment. After 14 hours (CHIKV-181/25) 
or 48 hours (LACV), cells were trypsinized, fixed in 1% PFA and permeabilized with a 0.1% 
saponin solution in HBSS and 10mM HEPES. CHIKV infected cells were stained with CHK11, 
a mouse monoclonal antibody specific to the E2 protein, and LACV infected cells were stained 
with supernatants from the hybridomas 807:31 and 807:33, kindly provided by Andrew Pekosz. 
Following secondary antibody staining with goat-anti mouse IgG-Alexa Fluor 647 (Life 
Technologies), cells were analyzed by flow cytometry using the FACSArray Flow Cytometer 
(BD Biosciences). Transduced populations were identified by GFP, and infected populations 
were identified by Alexa Fluor 647 staining. 
Generation of bulk CRISPR lines. Single guide RNAs (sgRNA) were identified using 
the online algorithm developed by the lab of Feng Zheng and the Broad Institute 
(www.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). Briefly, the algorithm 
determined a series of possible guides that could bind to the gene of interest and ranked them 
according to predicted specificity and efficacy. The top three ranked guides were chosen, flanked 
with the correct nucleotide sequences (Oligo 1: 5’-CACCG; Oligo 2: 5’-C and 3’-AAAC) to 
accommodate ligation into the LentiCRISPRv2 vector, and commercially produced (IDT). 
Guides are provided in Table 1. 
LentiCRISPRv2 (Addgene 52961) is a lentiviral plasmid with Cas9 and the puromycin 
resistance gene expressed under the EFS promoter, and a U6 promoter just upstream of a 2kb 
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filler region flanked by BsmBI restriction sites. The filler region was removed via BsmBI 
digestion and gel purification, and then replaced with sgRNAs via T4 DNA Ligase. The plasmids 
were then transformed, collected via Qiagen’s MiniPrep kit, and sequence verified using the 
following primer: U6 Fwd 5’-GAGGCCTATTTCCCATATTCC-3’.  
The LentiCRISPRv2 library was packaged in 293T cells in 6 well plates with pSPAX2 
(Addgene 12260) and pMD2.G (Addgene 12259), using the FuGENE HD (Roche) transfection 
reagent. After 48 hours, lentiviral supernatant was removed and collected. Low passage NIH-
3T3 cells plated in 12 well plates were then spinoculated with lentivirus and 10ug/ml polybrene 
for 30 minutes at room temperature at 1000 x g. The next day, cells were split 1:4 and given 
fresh complete DMEM with 2µg/ml puromycin to select for transduced cells. After 7 days of 
selection, cells were aliquoted and frozen down. 
IFN treatment, infection with CHIKV-181/25 and analysis were optimized to provide a 
consistent 4-6 fold difference between negative control, scrambled sgRNA, and STAT1 sgRNA 
bulk CRISPR lines. At 14 hours post infection, cells were harvested, fixed, stained and analyzed 
by flow cytometry as described above. 
Western Blotting. Negative control scrambled and Ifitm3 bulk CRISPR lines were lysed 
in RIPA and electrophoresed under reducing conditions on a 4-12% Bis-Tris NuPAGE gel with 
MES buffer according to the manufacturer’s instructions (Thermo Fisher). After transfer onto 
PVDF membranes (Thermo Fisher) using an iBlot apparatus (Thermo Fisher), proteins of 
interest were detected with mouse anti-β-actin (CST, 8H10D10), Polyclonal rabbit anti-Ifitm3 
(Proteintech, 11714-1-AP), HRP-conjugated anti-mouse IgG (Sigma Chemical), and HRP-
conjugated anti-rabbit IgG (Sigma Chemical). 
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Mice. Lamp3-/- mice were generated by CRISPR, deleting 11 or 335 nucleotide deletions 
in exon 2 of the Lamp3 gene, both of which result in a frame shift and a premature stop codon. 
Both alleles were backcrossed twice to C57BL/6J mice to remove potential off-target effects and 
then generated mouse lines using brother by sister mating. Ifit2-/- mice were made commercially 
(Taconic) in the C57BL/6 background, wherein exons 2 and 3 of the Ifit2 gene were flanked by 
flt sites and then excised via Flt recombinase. Mice were either infected in the footpad with 
CHIKV-LR at a final volume of 10ul, or with LACV with a final volume of 50ul, diluted in PBS. 
Viral burden of tissues or serum harvested were done by a focus forming assay. 
Viral growth kinetics. For viral yield assays, cells were plated (105 cells per well in a 
12-well plate) and in some experiments pretreated with specified doses of IFNβ for 12 hours. 
Cells then were infected with CHIKV at 37°C. One hour later, the plates were rinsed twice with 
warm PBS, and replaced with fresh DMEM supplemented with 10% FBS. Supernatants were 
collected at specific time points, and viral titers were determined by focus forming assay on Vero 
cells, as described (37, 48). 
Measurement of viral burden by qRT-PCR. Mouse tissue homogenates were 
processed for RNA using the Qiagen RNeasy kit. Serum samples were prepared using the 
Qiagen QIAmp Viral RNA kit. Viral titers were quantified to a standard curve of CHIKV and 
normalized to tissue weight or ml of serum. CHIKV RNA was detected using an E1 specific 
primer and probe set.  
Data and Statistical analysis. Flow cytometry data was analyzed using FloJo software. 
Analysis of the shRNA ISG screen and Z-score calculations were done on Microsoft Excel. 
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Student t-tests, Mann-Whitney or Dunnet’s multiple comparison ANOVA tests were performed 
with Prism Software (GraphPad, San Diego, CA). 
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RESULTS 
Screening for novel antiviral ISGs. A library comprised of 756 unique shRNAs, 
targeted against 243 putative murine ISGs was obtained commercially from Open Biosystems. 
These putative ISGs were identified from a collection of published microarray analyses of genes 
upregulated in vitro after treatment with Type I IFN. Each shRNA arrived inserted into the 
bicistronic pGIPZ lentiviral vector, which includes a GFP reporter (Fig 2.1A). Individual 
plasmids from the library were packaged into lentiviruses and transiently transduced into NIH-
3T3 cells in a 96 well format. Each plate contained negative scrambled controls and positive 
Stat1 shRNA transduced controls. After 72 hours, successful transduction was determined by 
GFP expression. Cells were then treated with IFNβ for 6 hours and infected with either CHIKV-
181/25 (MOI 5) or LACV (MOI 200) (Fig 2.1B). The administration of IFN and virus was 
optimized to obtain a low percentage of infectivity in the presence of IFN and a high percentage 
in the absence of IFN (3-7% and 70-80% in all transduced cells, respectively) in an attempt to 
skew towards the detection of antiviral ISGs. After 14 hours (CHIKV) or 48 hours (LACV), cells 
were processed and analyzed by flow cytometry (Fig 2.1C). The transduced (GFP+) cell 
population was analyzed to determine the percentage of infected cells (GFP+ Alexa Fluor 647+) 
in each well, and subsequently normalized to the percentage calculated in the scrambled controls.  
These ratios were then ranked by Z-score. Any shRNA construct with a Z-score of 1.5 (one and a 
half standard deviations above the mean) was considered a ‘hit’ in these screens. 
In the CHIKV-181/25 screen, a total of 33 shRNAs, corresponding to 28 unique ISG 
targets were identified (Fig 2.2A). These included shRNAs targeting the positive control (Stat1) 
ISGs with well characterized antiviral function (Stat2 and Ifit1), transcription factors (Irf8), and 
proteins involved in antigen presentation (β2m and H2-T). After manually eliminating genes that 
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were already characterized, deemed difficult to characterize (such as transcription factors, or 
genes canonically involved in the adaptive immune response), a final list of 21 candidate ISGs 
was generated. In the LACV screen, a total of 49 shRNAs, corresponding to 46 unique ISG 
targets were identified (Fig 2.2B). Like the CHIKV screen, ISGs with known antiviral potency 
and mechanism were included. Manual curation of these targets resulted in a final list of 30 
unique ISG targets, three of which were also found in the CHIKV screen (Agt, Ifi47, Lypla1). A 
table of the final ISGs targets and their known functions are included in Table 2.1. 
 Independent assessment of the top candidate ISG targets. To better understand the 
efficiency of knockdown and potential off-target effects of the library, the Z-scores of all the 
shRNAs against the top ISG target hits were directly compared (Fig 2.3). Strikingly, for most of 
the gene targets, the majority of the corresponding shRNAs had a Z-score well below 1.5. Even 
for the positive control, Stat1, only 3 of the 6 shRNAs had a Z-score greater than 1.5, suggesting 
only 50% efficiency of this library at best. Combined with the manufacturer’s claim that “at least 
one of three constructs is guaranteed to reduce target mRNA levels by 70% or more,” (Open 
Biosystems) the reliability of the shRNA screen is put into question. 
 To independently verify the top hits, we decided to use the gene editing technology 
CRISPR to generate targeted knockout cell lines. We prioritized targets identified in the CHIKV-
181/25 screen over the LACV screen because there are more reagents available to evaluate 
CHIKV pathogenesis. An sgRNA library was first developed using the online designer tool from 
the Broad Institute (www.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). The top 3 
guides were picked for each ISG target (Table 2.2) and ligated into the LentiCRISPRv2 plasmid 
(Fig 2.4), which also expresses Cas9 and the puromycin resistance gene. After packaging, the 
CRISPR library was transduced into NIH-3T3 cells and maintained under 2µg/ml of puromycin 
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selection for 7 days. After selection, the cell lines were aliquoted and frozen down. Efficacy of 
gene editing was tested by treating the scrambled negative control and Stat1 targeted lines with 
increasing doses of murine IFNβ for 6 hours and then infecting with different MOIs of CHIKV-
181/25 for 14 hours. By flow cytometry, all 3 Stat1 bulk CRISPR lines were more susceptible to 
infection than scrambled controls, especially as the concentration of IFN was increased (Fig 2.5). 
However, analysis of the bulk CRISPR library yielded no clear antiviral phenotype, with only a 
few individual lines attaining a 2-fold change increase in infection compared to the scrambled 
controls (Fig 2.6). A closer analysis was performed of six ISG targets that had at least one bulk 
CRISPR line infected higher than 1-fold. After treating cells with increasing doses of IFN and 
virus, only the Ccng1 bulk CRISPR lines had a consistent, increased fold change in infection 
compared to scrambled controls. Furthermore, the Ccng1 bulk CRISPR lines showed differences 
in infection without IFN treatment, suggesting that the Ccng1 phenotype may not be IFN 
dependent (Fig 2.7). 
 Since the CRISPR screen only validated one gene identified in the shRNA screen, an 
additional positive control was included. Even though Stat1 has been used consistently and 
successfully for similar ISG screens as a positive control, adding a known, less potent antiviral 
ISG could assist in fine tuning the IFN dosage and infection conditions to tease out the effects of 
the more moderately acting antiviral genes. The ISG Ifitm3 was chosen, as we had recently 
published its antiviral effects on alphaviruses (discussed in Chapter 3 of this dissertation). 
Unfortunately, no variation in IFN dosage or MOI tested could induce a satisfactory difference in 
infectivity between the Ifitm3 bulk CRISPR lines and the negative controls (Fig 2.8A). By 
Western blot, Ifitm3 can still be detected in all three lines, and expression increased if the cells 
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were pre-treated with IFNβ (Fig 2.8B). This is likely due to the genetic heterogeneity of the bulk 
cells. 
Alternative approaches to independently assess target ISGs.  Knockout mice were 
available for four of the ISGs identified in our shRNA screens. Ifitm3 and Lamp3 were identified 
in both the CHIKV and LACV screens, while Ifit2 and β2m were identified in the LACV screen 
only. As Ifitm3 had previously been described to restrict orthobunyaviruses in vitro, we decided 
to follow up on its potential role in CHIKV instead, using Ifitm3-/- and Ifitm locus deletion MEFs. 
Further discussion of these experiments will be in Chapter 3 of this dissertation.  
Ifit2 is a potent antiviral ISG that has been shown to restrict viral replication by binding 
to subunits eIF3, which is required for initiation and translation (14). In the context of WNV 
infection, it was shown that Ifit2 restricts viral replication in the CNS, and only functions in a 
subset of primary cells, like cerebellar granule cells and macrophages, but not MEFs (88). The 
lack of restriction was also observed in growth kinetics studies with LACV in MEFs (data not 
shown). In addition, no significant differences weight in loss and death were observed in 8 to 10 
week old Ifit2-/- and WT mice infected with 105 FFU of LACV in the footpad (Fig 2.9). 
β2m, or beta-2-microglobulin, is canonically known for its role in stabilizing the structure 
of MHCI, which is required for presentation of cellular antigen to CD8+ T cells (89). Due to its 
importance in adaptive immunity, studying its potential role as an antiviral ISG in vivo would be 
difficult. Instead, β2mKbDb triple knockout MEFs were infected with CHIKV after treatment 
with IFN. Interestingly, we noticed that the triple knockout cells were less prone to infection 
after 14 hours than MEFs from WT littermate controls (Fig 2.10). Although an interesting 
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observation, additional experiments were not performed, and due to the foreseeable difficulty of 
properly studying the non-canonical properties of β2m. 
 
Lamp3 is an endosomal-lysosomal associated protein that is highly expressed in the cells 
of the airway, and in macrophages and dendritic cells (90), though there has been no extensive 
study on its upregulation in other tissues upon IFN stimulation. Recent unpublished observations 
have shown that Lamp3 is highly protective against MERS-Coronavirus pathogenesis. One study 
in A549 cells suggest that Lamp3 is actually proviral, and is required for the IAV nucleoprotein 
and titers (91). In the context of CHIKV infection, no differences were seen after 14 hours by 
flow cytometry, nor were any differences seen by growth kinetics (Fig 2.11A-B). When infected 
subcutaneously with 104 FFU, WT and Lamp3-/- mice had comparable levels of titer in the 
spleen, ankle joints and serum at day 1 and 2 post infection by focus forming assay (Fig 2.12). 
To determine if Lamp3 had a possible role in maintaining or clearing the chronic viral RNA seen 
in the feet and spleen, infected mice were assayed by qPCR at 21 days post infection. Again, no 
differences in viral RNA titer were observed (Fig 2.13). The role of Lamp3 in LACV 
pathogenesis has not been studied. 
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DISCUSSION 
 To identify novel antiviral ISGs, a murine shRNA library targeting 243 genes was tested 
against the attenuated alphavirus CHIKV-181/25 and the orthobunyavirus LACV. Using 
shRNAs to knockdown target genes in vitro allowed for the identification of genes with antiviral 
function in the context of physiological response to IFN treatment. In addition, the attenuated 
alphavirus and orthobunyavirus were used in an attempt to find antiviral ISGs whose functions 
were either likely masked by pathogenic strains, or to identify completely novel, virus specific 
gene targets. From the shRNA screen, a total of 28 and 46 unique ISGs were identified that were 
deemed antiviral against CHIKV-181/25 and LACV, respectively. These genes included known 
antiviral ISGs like Stat 2, Ifit1 and Ifit2, Ifitm3, and Mx1, as well as transcription factors like Irf8 
and Irf9. However, a lack of reliability of knockdown by the shRNA library led to a concern that 
the unique ISGs in these top hits were the result of off-target effects.  
Independent assessment of these targets using bulk CRISPR edited NIH-3T3 cells have 
thus far proven to be incomplete, and further optimization is needed before the hits can be 
properly analyzed. The current conditions of the CRISPR screen are unable to identify novel 
antiviral ISGs less potent than Stat1 or as effective as Ifitm3. Since CRISPR acts by inducing 
breaks and random repair of genomic DNA, we cannot guarantee that enough alleles in the bulk 
population of cells have been knocked out to see an appreciable change in phenotype. This issue 
is compounded by the fact that NIH-3T3 cells are hypertriploid, increasing the likelihood that 
some CRISPR targeted cells have at least one functioning target allele. In fact, by Western blot 
analysis of the Ifitm3 bulk CRISPR lines, the protein could still be detected, especially in 
samples where the cells were stimulated with IFN.  
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To salvage the CRISPR screen, we would have to generate and validate (by DNA 
sequencing and, if reliable antibodies are available, by protein detection) clonal knockout lines 
for each ISG target from the bulk populations. This way, we can cleanly assess the role of each 
target ISG without background noise from partially affected or unaltered alleles. Furthermore, 
any potential trans functions an ISG may have will no longer be a factor. Positive hits should be 
re-assessed on other cell lines (such as MEFs, BV2s, and human lines like HeLas and 293Ts) to 
address the possibility that the phenotype observed is unique only to NIH-3T3s. 
A better approach for this screen or for future high throughput screens could be to try 
CRISPR interference (CRIPSRi), which represses gene expression at the transcriptional level, 
physically blocking the progress of RNA polymerase. Using this knockdown method, which can 
be stably transduced, heterogeneity of mutations at the genomic level can be avoided while we 
can take advantage of the specificity of the sgRNA-dCas9 system. Validation can be done by 
RT-PCR (presence or lack of mRNA) and by Western blot. One caveat is that the efficiency of 
knockdown decreases the further the target is from the transcription start site, which may limit 
the number of possible sgRNA candidates per gene.  
Another option would be to step away from the CRISPR lines and see if ectopic 
expression of the ISG targets yields any results. This approach is beneficial because we can 
theoretically track the cells that have incorporated the expression vector by flow cytometry, and 
determine the antiviral potency of each target ISG in the absence of IFN stimulation. However, 
this runs contrary to the spirit of the original screen, which was designed to understand a target 
ISGs importance in a physiological antiviral environment. 
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 In summary, we attempted to identify novel antiviral ISGs in a high-throughput manner 
using a gene knockdown system and viruses that are either attenuated or not previously tested in 
prior, similar studies. This shRNA based screen identified a series of novel and previously 
described ISG targets. Due to the unreliability of the knockdown system, the validity of these 
hits is questionable at best. However, by using available knockout reagents for a select number 
of the top ISGs, Ifitm3 was found to restrict CHIKV infection. 
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Figure 2.1 
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Figure 2.1. Lentiviral based shRNA screen for ISGs that restrict alphavirus or 
orthobunyavirus infection. (A) Plasmid map of the pGIPZ plasmid containing the shRNA oligo 
and the IRES GFP reporter. (B) The shRNA library targeting ISGs were packaged and 
transduced into NIH-3T3 cells. 72 hours later, cells were treated with IFNβ (2.5 IU/ml for 
CHIKV and 1 IU/ml for LACV) for 6 hours then infected with CHIKV-181/25 or LACV at MOI 
5 or MOI 200, respectively. After 14 hours (CHIKV) or 48 hours (LACV), cells were processed 
for flow cytometry. (C) Representative flow plots of non-silencing control (NSC) transduced 
cells or Stat1 shRNA transduced control cells infected with CHIKV-181/25. Transduction 
efficiency is determined by the expression of GFP on the x-axis and infection efficiency is 
shown by viral envelope staining on the y-axis. 
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Figure 2.2 
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Figure 2.2. Analysis of the ISG screen. After flow cytometry, the percentage of infected cells 
of the total transduced population for every well was normalized to that of the non-silencing 
control. This ratio was normalized by Z-score and ranked for (A) CHIKV-181/25 and for (B) 
LACV. The top hits with a Z-score of 1.5 and above are listed on the table to the right. Each dot 
represents a single shRNA in the library. 
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Figure 2.3 
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Figure 2.3. Efficacy of the shRNA library. The Z-scores of all the shRNAs targeting the top 
ranked ISGs from the CHIKV (top) and the LACV (bottom) screens were directly compared. 
Dotted lines mark Z-score at 1 and 1.5 for the CHIKV graph, and 0, 1, 1.5 and 2 for the LACV 
graph. Dashed lines represent the the median value. Z-score threshold for both screens was 1.5 
(1.5 standard deviations above the mean). 
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Figure 2.4 
 
 
 
 
Figure 2.4. CRISPR knockout of select ISGs. Plasmid map of the LentiCRIPSRv2 vector, 
which contains a 2kb filler space under the U6 promoter. This spacer is replaced by the sgRNA 
oligo. The Cas9 and puromycin resistance gene cassette are under the EFS promoter.  
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Figure 2.5 
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Figure 2.5. Demonstration of the efficacy of the CRISPR gene editing system.  Non-silencing 
control lines and Stat1 bulk CRISPR lines were pretreated with the indicated concentration of 
IFNβ for 6 hours before being infected for 14 hours with CHIKV 181/25 at an MOI of 0.5, 1 or 
5. Percentages of infection were then determined by flow cytometry. The numbers above 
indicate the average fold-difference in infection between the control and the Stat1 bulk CRISPR 
lines. 
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Figure 2.6 
 
Figure 2.6. Attempt at validating the antiviral phenotype of select ISGs using bulk CRISPR 
lines.  NIH-3T3 bulk CRISPR lines were treated with IFNβ (3 IU/ml) for 6 hours, then infected 
with CHIKV 181/25 at MOI 1 for 14 hours. Cells were then analyzed by flow cytometry. Fold-
differences in infection versus control lines are shown here. The dotted line indicates a one-fold 
change.
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Figure 2.7 
 
 
 
 
 
 
 
 
Figure 2.7. Analysis of select bulk CRISPR lines. The bulk CRISPR lines of six ISG targets 
from the initial screen were further tested to verify the presence of an antiviral phenotype. Cell 
lines were pretreated at the indicated concentrations of IFNβ for 6 hours before being infected 
with MOI 1 of CHIKV 181/25 for 14 hours. Cells were analyzed by flow cytometry and the fold 
differences in infection compared to controls are graphed. The dotted line indicates a one-fold 
difference. 
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Figure 2.8 
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Figure 2.8. Attempt at showing an antiviral phenotype with Ifitm3 bulk CRISPR lines. (A) 
NIH-3T3 bulk CRISPR lines were treated with the indicated dose of IFNβ for 6 hours and then 
infected with various MOIs of CHIKV 181/25 for 14 hours before being analyzed by flow 
cytometry. (B) Western blot of control and Ifitm3 bulk CRISPR lines with or without 3 IU/ml 
IFNβ treatment for 6 hours. 
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Figure 2.9 
 
 
 
 
 
 
Figure 2.9. Pathology of LACV in Ifit2-/- mice. 8 week old WT and Ifit2-/- mice were infected 
with  105 FFU into the footpad and followed for weight loss. No mortality was seen during the 
course of infection. 
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Figure 2.10 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Susceptibility of β2mKbDb triple knockout MEFs to infection by CHIKV 
181/25. MEFs were treated with the indicated concentration of IFNβ for 6 hours before being 
infected with various MOIs of CHIKV 181/25 for 14 hours. Cells were analyzed by flow 
cytometry. Means were compared by Student t-test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 2.11 
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Figure 2.11. CHIKV infection is not enhanced by Lamp3 in vitro. WT and Lamp3-/- MEFs 
were treated with IFNβ and then infected with either (A) MOI 0.1 or (B) MOI 5 of CHIKV 
181/25. Virus Statistically significant but inconsequential differences were observed in the 
multistep growth kinetics (A) of CHIKV in the absence of IFN, as well as in percent infection of 
MEFs at low dose of IFN. No differences were seen in viral growth kinetics at (B) high MOI, nor 
do we see a notable difference in infection of MEFs after 14 hours. Means were compared by 
Student t-test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 2.12 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Lamp3 does not protect against early viral CHIKV titers in the tissues. 4 week 
old WT and Lamp3-/- mice were injected with 1000 FFU of CHIKV-LR and were sacrified at 1 
day post infection. Viral burdens in the serum, spleen, ankles, and quadriceps were analyzed by 
focus forming assay. No statistical differences were identified by Mann-Whitney. 
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 Figure 2.13 
 
 
 
 
 
 
 
 
 
Figure 2.13. Lamp3 does not affect the chronic burden of CHIKV in mice. 4 week old mice 
were infected with 1000 FFU of CHIKV-LR and harvested at 21 days post infection. Viral 
burden in the ankles and the spleen were determined by quantitative PCR. No statistical 
difference was observed by Mann-Whitney. 
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Table 2.1. Final list of CHIKV and LACV antiviral ISGs identified from the shRNA screen 
 
CHIKV  targets  
Symbol Full Name Known functions (NCBI) 
Agt Angiotensinogen Cleaved by renin in response to lowered blood pressure to form 
angiotensin-1. 
Akt3 Thymoma viral 
proto-oncogene 3 
Serine/threonine kinase that plays a key in regulating cell survival, 
insulin signaling, angiogenesis and tumor formation. Akt is a 
downstream mediator of the PI 3-K pathway, which results in the 
recruitment of Akt to the plasma membrane. 
Atf3 Activating 
transcription factor 3 
Binds cAMP.  Represses transcription from promoters with ATF sites. 
Ccng1 Cyclin G1 May play a role in growth regulation. Is associated with G2/M phase 
arrest in response to DNA damage. May be an intermediate by which 
p53 mediates its role as an inhibitor of cellular proliferation 
Cd47 CD47 antigen Cell adhesion receptor on platelets. Modulation of integrins. May be 
involved in membrane permeability changes induced following virus 
infection. 
Cfb Complement factor B Component of the alternative complement pathway. 
Dock4 Dedicator of 
cytokinesis 4 
Involved in regulation of adherens junction between cells. Plays a role 
in cell migration. Functions as a guanine nucleotide exchange factor 
(GEF), which activates Rap1 small GTPase by exchanging bound 
GDP for free GTP. 
Erlec1 RIKEN cDNA 
4933407N01 
N-glycan recognition in the ER and may regulate glycoprotein traffic 
Fam129a Family with sequence 
similarity 129, 
member A 
Regulates phosphorylation of a number of proteins involved in 
translation regulation including EIF2A, EIF4EBP1 and RPS6KB1. 
May be involved in the endoplasmic reticulum stress response 
Gtpbp2 GTP binding protein 
2 
Upregulated in mouse peritoneal macrophages. 
Ifi202b Interferon activated 
gene 202B 
Unknown function 
Ifi47 Interferon gamma 
inducible protein 47 
Unknown function 
Kbtbd8 Kelch repeat and 
BTB (POZ) domain 
containing 8 
Unknown function 
Lamp3 Lysosomal-associated 
membrane protein 3 
May play a role in dendritic cell function and in adaptive immunity. 
Lap3 Leucine 
aminopeptidase 3 
Presumably involved in the processing and regular turnover of 
intracellular proteins. Catalyzes the removal of unsubstituted N-
terminal amino acids from various peptides. 
Lypla1 Lysophospholipase 1 Hydrolyzes fatty acids from S-acylated cysteine residues in proteins 
such as trimeric G alpha proteins or HRAS. Has depalmitoylating 
activity toward KCNMA1. Has low lysophospholipase activity 
Ppp2r2a Protein phosphatase 
2, regulatory subunit 
B, alpha isoform 
one of the four major Ser/Thr phosphatases, and it is implicated in the 
negative control of cell growth and division 
Reep3 Receptor accessory 
protein 3 
Microtubule-binding protein required to ensure proper cell division 
and nuclear envelope reassembly by sequestering the endoplasmic 
reticulum away from chromosomes during mitosis. Probably acts by 
clearing the endoplasmic reticulum membrane from metaphase 
chromosomes. 
Tmod3 Tropomodulin 3 
 
Blocks the elongation and depolymerization of the actin filaments at 
the pointed end. The Tmod/TM complex contributes to the formation 
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of the short actin protofilament, which in turn defines the geometry of 
the membrane skeleton 
Trim34a Tripartite motif-
containing 34a 
Unknown function 
Trim69 Tripartite motif-
containing 69 
 
The mouse ortholog of this gene is specifically expressed in germ 
cells at the round spermatid stages during spermatogenesis and, when 
overexpressed, induces apoptosis. Alternatively spliced transcript 
variants encoding distinct isoforms have been described. 
   
LACV  targets  
Symbol Full Name Known functions (NCBI) 
Agt Angiotensinogen Cleaved by renin in response to lowered blood pressure to form 
angiotensin-1. 
Btc Betacellulin Growth factor that binds to EGFR, ERBB4 and other EGF receptor 
family members. Potent mitogen for retinal pigment epithelial cells 
and vascular smooth muscle cells. 
Ccdc50 Coiled-coil domain 
containing 50 
Involved in EGFR signaling. Mutations cause hearing loss in mice. 
Dhx58 DEHX box 
polypeptide 58 
Acts as a regulator of DDX58/RIG-I and IFIH1/MDA5 mediated 
antiviral signaling. Cannot initiate antiviral signaling as it lacks the 
CARD domain required for activating MAVS/IPS1-dependent 
signaling events. 
Gbp3 Guanylate binding 
protein 3 
Specifically bind guanine nucleotides (GMP, GDP, and GTP) and 
contain two of the three consensus motifs found in typical GTP-
binding proteins. Exhibits antiviral activity against influenza virus. 
Gbp4 Guanylate binding 
protein 4 
Binds GTP, GDP and GMP. Hydrolyzes GTP very efficiently; GDP 
rather than GMP is the major reaction product. Plays a role in 
erythroid differentiation  
Htr1d serotonin receptor 1D G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also 
functions as a receptor for ergot alkaloid derivatives, various 
anxiolytic and antidepressant drugs and other psychoactive 
substances. May play a role in vasoconstriction 
Ifi203 Interferon activated 
protein 203 
Unknown function 
Ifi47 Interferon gamma 
inducible protein 47 
Unknown function 
Igtp Interferon gamma 
induced GTPase 
Unknown function 
Lypla1 Lysophospholipase 1 Hydrolyzes fatty acids from S-acylated cysteine residues in proteins 
such as trimeric G alpha proteins or HRAS. Has depalmitoylating 
activity toward KCNMA1. Has low lysophospholipase activity 
Mov10 Moloney leukemia Probable RNA helicase. Required for RNA-mediated gene silencing 
by the RNA-induced silencing complex (RISC). Required for both 
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virus 10 miRNA-mediated translational repression and miRNA-mediated 
cleavage of complementary mRNAs by RISC. Also required for 
RNA-directed transcription and replication of the human hepatitis 
delta virus (HDV). 
Pnpt1 Polyribonucleotide 
protein 
nucleotidyltransferase 
1 
RNA-binding protein implicated in numerous RNA metabolic 
processes.  
Psmb8 Proteasome subunit, 
beta type 8 
Replacement of PSMB5 by PSMB8 increases the capacity of the 
immunoproteasome to cleave model peptides after hydrophobic and 
basic residues. Acts as a major component of interferon gamma-
induced sensitivity. Plays a key role in apoptosis via the degradation 
of the apoptotic inhibitor MCL1. May be involved in the 
inflammatory response pathway. 
Rps3a Ribosomal protein 
S3A 
May play a role during erythropoiesis through regulation of 
transcription factor DDIT3 
Rtp4 Receptor transporter 
protein 4 
Probable chaperone protein which facilitates trafficking and 
functional cell surface expression of some G-protein coupled 
receptors (GPCRs). Promotes functional expression of the bitter taste 
receptor TAS2R16  
Samd9l Sterile alpha motif 
domain containing 9-
like 
Unknown function 
Sema6d Semaphorin 6D Shows growth cone collapsing activity on dorsal root ganglion (DRG) 
neurons in vitro. May be a stop signal for the DRG neurons in their 
target areas, and possibly also for other neurons. May also be involved 
in the maintenance and remodeling of neuronal connections. 
Serping1 Complement 1 
inhibitor 
forms a proteolytically inactive stoichiometric complex with the C1r 
or C1s proteases. May play a potentially crucial role in regulating 
important physiological pathways including complement activation, 
blood coagulation, fibrinolysis and the generation of kinins. 
Slc16a4 Solute carrier family 
16, member 4 
Proton-linked monocarboxylate transporter. Catalyzes the rapid 
transport across the plasma membrane of many monocarboxylates 
such as lactate, pyruvate, branched-chain oxo acids derived from 
leucine, valine and isoleucine, and the ketone bodies acetoacetate, 
beta-hydroxybutyrate and acetate  
Slc25a28 Solute carrier family 
25, member 28 
Mitochondrial iron transporter that mediates iron uptake. 
Snx5 Sorting nexin 5 Involved in several stages of intracellular trafficking. 
Sp100 Nuclear antigen 
Sp100 
involved in a large number of physiological processes including cell 
growth, differentiation and apoptosis. 
Tgm2 Transglutaminase 2 Catalyzes the cross-linking of proteins and the conjugation of 
polyamines to proteins. 
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Trim25 Tripartite motif-
containing 25 
Expression of the gene is upregulated in response to estrogen, and it is 
thought to mediate estrogen actions in breast cancer as a primary 
response gene. 
Ttc39b Tetratricopeptide 
repeat domain 39b 
Unknown function 
Ubd Ubiquitin D Constitutively expressed in mature dendritic cells and B-cells. Mostly 
expressed in the reticuloendothelial system (e.g. thymus, spleen), the 
gastrointestinal system, kidney, lung and prostate gland 
Ugt1a6a UDP 
glycosyltransferase 
UDPGT is of major importance in the conjugation and subsequent 
elimination of potentially toxic xenobiotics and endogenous 
compounds. This isoform has specificity for phenols. Isoform 3 lacks 
transferase activity but acts as a negative regulator of isoform 1  
Xdh xanthine 
dehydrogenase 
Key enzyme in purine degradation. Catalyzes the oxidation of 
hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric 
acid. Contributes to the generation of reactive oxygen species. Has 
also low oxidase activity towards aldehydes  
Zeb2 Zinc finger E-box 
binding homeobox 2 
Transcriptional inhibitor that binds to DNA sequence 5-CACCT-3 in 
different promoters. Represses transcription of E-cadherin. 
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Table 2.2. sgRNAs for select ISGs to generate bulk CRISPR knockout cell lines. 
Gene 
Name 
CRISPR 
line Sequence 5'-->3' 
Gene 
Name 
CRISPR 
line Sequence 5'-->3' 
Stat1 1 caccgGGATAGACGCCCAGCCACTG Kbtbd8 1 caccgCCTGTGACGATATCTAGACA 
   aaacCAGTGGCTGGGCGTCTATCCc    aaacTGTCTAGATATCGTCACAGGc 
          
  2 caccgTGTGATGTTAGATAAACAGA   2 caccgAGACAGTGACGATTTAAATG 
   aaacTCTGTTTATCTAACATCACAc    aaacCATTTAAATCGTCACTGTCTc 
          
  3 caccgCGGCTGTCGTTCTACCACGA   3 caccgAAGACTCCAATAGAATTCTG 
   aaacTCGTGGTAGAACGACAGCCGc    aaacCAGAATTCTATTGGAGTCTTc 
            
Ccng1 1 caccgGGATCAAATCAGTCGCCAGT Lamp3 1 caccgAGAGTAGGCCTAGGAACTAG 
   aaacACTGGCGACTGATTTGATCCc    aaacCTAGTTCCTAGGCCTACTCTc 
          
  2 caccgGGAGTCTAGATGTCAGCCAA   2 caccgCCCAGTTATATAGTTGACAA 
   aaacTTGGCTGACATCTAGACTCCc    aaacTTGTCAACTATATAACTGGGc 
          
  3 caccgACGACACCTTGCCATTTGAG   3 caccgTCATCTACTGACGATACCAT 
   aaacCTCAAATGGCAAGGTGTCGTc    aaacATGGTATCGTCAGTAGATGAc 
            
Erlec1 1 caccgCCAGGCCAGTTGACTCGGAA Ifi202b 1 caccgGGGAAACCAATATTACACTC 
   aaacTTCCGAGTCAACTGGCCTGGc    aaacGAGTGTAATATTGGTTTCCCc 
          
  2 caccgACTTCCACTTGTGACAAGTG   2 caccgCCAAAAAAGAACATTAGCAA 
   aaacCACTTGTCACAAGTGGAAGTc    aaacTTGCTAATGTTCTTTTTTGGc 
          
  3 caccgTCCAACTGTCTTAGTGTGAG   3 caccgTGGCCAGATGAATCACTGGA 
   aaacCTCACACTAAGACAGTTGGAc    aaacTCCAGTGATTCATCTGGCCAc 
            
Atf3 1 caccgCCAGCGCAGAGGACATCCGA Ifi47 1 caccgGGTCTAGATAAGCGTCTGCG 
   aaacTCGGATGTCCTCTGCGCTGGc    aaacCGCAGACGCTTATCTAGACCc 
          
  2 caccgTCCTCAAATACCAGTGACCC   2 caccgTTGGAGATCAGGAAGATGCA 
   aaacGGGTCACTGGTATTTGAGGAc    aaacTGCATCTTCCTGATCTCCAAc 
          
  3 caccgTACCGTCAACAACAGACCCC   3 caccgCTGATTAATGCAGAGTACTG 
   aaacGGGGTCTGTTGTTGACGGTAc    aaacCAGTACTCTGCATTAATCAGc 
            
Fam129a 1 caccgATTGTAACTTACTCCAAACC Lypla1 1 caccgTTCACGGATTGGGAGATACA 
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   aaacGGTTTGGAGTAAGTTACAATc    aaacTGTATCTCCCAATCCGTGAAc 
          
  2 caccgACGGAGCTTAACCTTCTCGA   2 caccgCGCGGCGGTGGCCTTCCGGG 
   aaacTCGAGAAGGTTAAGCTCCGTc    aaacCCCGGAAGGCCACCGCCGCGc 
          
  3 caccgCAGACCTCAAAACCGCCATG   3 caccgTGGACAGATGTATTTGATGT 
   aaacCATGGCGGTTTTGAGGTCTGc    aaacACATCAAATACATCTGTCCAc 
            
Gtpbp2 1 caccgCCAGTTCCTAGATCTCCGTG Lap3 1 caccgGGGGTGCCTCGGTTGCATTG 
   aaacCACGGAGATCTAGGAACTGGc    aaacCAATGCAACCGAGGCACCCCc 
          
  2 caccgACTGGACAGTGTAAATATAG   2 caccgGTCCACCGCAGACATGACGA 
   aaacCTATATTTACACTGTCCAGTc    aaacTCGTCATGTCTGCGGTGGACc 
          
  3 caccgCCTGTGTGCTAAGACCACAG   3 caccgAAGTGCCAGTAGTAAAACCA 
   aaacCTGTGGTCTTAGCACACAGGc    aaacTGGTTTTACTACTGGCACTTc 
            
Dock4 1 caccgCCATATTGGAGATCACTAGT Ppp2r2a 1 caccgAAAAGAGGAACACTTACCGT 
   aaacACTAGTGATCTCCAATATGGc    aaacACGGTAAGTGTTCCTCTTTTc 
          
  2 caccgGGTAGCGGGTAGTATCCTGA   2 caccgCAAACGTGTTACAGCTGTTG 
   aaacTCAGGATACTACCCGCTACCc    aaacCAACAGCTGTAACACGTTTGc 
          
  3 caccgATGAAATCCTCGATCTGCGA   3 caccgGATGTGATAAGTGTGGGCGT 
   aaacTCGCAGATCGAGGATTTCATc    aaacACGCCCACACTTATCACATCc 
            
CFB 1 caccgTATGACGGTTACACTCTCCG Trim69 1 caccgCGGAACCAGTCGTTACACAG 
   aaacCGGAGAGTGTAACCGTCATAc    aaacCTGTGTAACGACTGGTTCCGc 
          
  2 caccgCATGTACGACACCCCTCAAG   2 caccgAAGAAGTTACCCCTGCTCAA 
   aaacCTTGAGGGGTGTCGTACATGc    aaacTTGAGCAGGGGTAACTTCTTc 
          
  3 caccgTCTGCAGGATTGCACAACAT   3 caccgAGGATGCACGGTTGTCTATG 
   aaacATGTTGTGCAATCCTGCAGAc    aaacCATAGACAACCGTGCATCCTc 
            
Agt 1 caccgGGAAGGGGTGGATGTATACG Tmod3 1 caccgTTCGGTTAGCACCGACCTCG 
   aaacCGTATACATCCACCCCTTCCc    aaacCGAGGTCGGTGCTAACCGAAc 
          
  2 caccgTGGATAAATCCAGAGAGCGT   2 caccgTGTAGGGCACATAATCGTCC 
   aaacACGCTCTCTGGATTTATCCAc    aaacGGACGATTATGTGCCCTACAc 
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  3 caccgCTCCCGACTAGATGGACACA   3 caccgGATGTGCTGGGAAGTAGTAA 
   aaacTGTGTCCATCTAGTCGGGAGc    aaacTTACTACTTCCCAGCACATCc 
            
Akt3 1 caccgCCGTAGCCGACCGATTGCAG Reep3 1 caccgCGTGAAGACGAAAAACGTCA 
   aaacCTGCAATCGGTCGGCTACGGc    aaacTGACGTTTTTCGTCTTCACGc 
          
  2 caccgAATTTGATGCTAGATAAGGA   2 caccgGCTGTCGCCCTACACTAGAG 
   aaacTCCTTATCTAGCATCAAATTc    aaacCTCTAGTGTAGGGCGACAGCc 
          
  3 caccgCTGCACCATAGAAACGTGTG   3 caccgATCTTCAGCTCATAGTACAG 
   aaacCACACGTTTCTATGGTGCAGc    aaacCTGTACTATGAGCTGAAGATc 
            
CD47 1 caccgATCAGCCTGTTCTTACGAGG Trim34a 1 caccgGACAGGCTTGGCATACACGG 
   aaacCCTCGTAAGAACAGGCTGATc    aaacCCGTGTATGCCAAGCCTGTCc 
          
  2 caccgGGATAAGCGCGATGCCATGG   2 caccgGAGAATCTAGTACCACACAC 
   aaacCCATGGCATCGCGCTTATCCc    aaacGTGTGTGGTACTAGATTCTCc 
          
  3 caccgCACTTCATGCAATGAAACTG   3 caccgGCTTAGAAGAATCCTGGACA 
   aaacCAGTTTCATTGCATGAAGTGc    aaacTGTCCAGGATTCTTCTAAGCc 
            
negative 
control 1 caccgACGGAGGCTAACGTCGCAA Ifitm3 1 caccgCTGACAGAAGCCGATCCGTG 
   aaacTTGCGACGTTAGCCTCCGTc    aaacCTCGGATCGGCTTCTGTCAGc 
          
  2 caccgCGCTTCCGCGCGGCCCGTTCAA   2 caccgAATCAAGGAAGAATATGAGG 
   aaacTTGAACGGGCCGCGCGGAAGCGc    aaacCCTCATATTCTTCCTTGATTc 
          
  3 caccgATCGTTTCCGCTTAACGGCG   3 caccgGTCTAGGGATCGGAAGATGG 
   aaacCGCCGTTAAGCGGAAACGATc    aaacCCATCTTCCGATCCCTAGACc 
            
 
Sequences in bold correspond to the sgRNA oligo. Nucleotides in lower case correspond to the 
flanking sequence required to ligate the oligos to the LentiCRISPRv2 vector. 
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Chapter 3: Characterization of murine Ifitm3 as an antiviral ISG against alphaviruses in 
vitro and in vivo 
 
This chapter is essentially as published in Journal of Virology:  
“The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic 
and Encephalitic Alphaviruses” Poddar S, Hyde JL, Gorman MS, Farzan M and Diamond MS. 
October 2016, vol 90, no.19 8780-8794. 
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ABSTRACT 
Host cells respond to viral infections by producing type I interferon (IFN), which induces 
the expression of hundreds of interferon stimulated genes (ISGs). Although ISGs mediate a 
protective state against many pathogens, the antiviral functions of the majority of these genes 
have not been identified. IFITM3 is a small transmembrane ISG that restricts a broad range of 
viruses including orthomyxoviruses, flaviviruses, filoviruses, and coronaviruses. Here, we show 
that alphavirus infection is increased in Ifitm3-/- and Ifitm locus deletion (Ifitm-del) fibroblasts, 
and reciprocally, reduced in fibroblasts trans-complemented with Ifitm3. Mechanistic studies 
showed that Ifitm3 did not affect viral binding or entry, but inhibited pH-dependent fusion. In a 
murine model of chikungunya virus arthritis, Ifitm3-/- mice sustained greater joint swelling in the 
ipsilateral ankle at days 3 and 7 post infection, and this correlated with higher levels of pro-
inflammatory cytokines and viral burden. Flow cytometric analysis suggested that Ifitm3-/- 
macrophages from the spleen were infected at greater levels than observed in wild-type (WT) 
mice, results that were supported by experiments with Ifitm3-/- bone marrow derived 
macrophages. Ifitm3-/- mice also were more susceptible than WT mice to lethal alphavirus 
infection with Venezuelan equine encephalitis virus, and this was associated with greater viral 
burden in multiple organs. Collectively, our data define an antiviral role for Ifitm3 in restricting 
infection of multiple alphaviruses. 
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INTRODUCTION 
 The type I interferon (IFN) response is a critical factor that orchestrates innate protection 
against viral pathogens. Upon detection of pathogen-associated molecular patterns (PAMPs), 
host cells produce type I IFN, which in turn induces expression of hundreds of IFN stimulated 
genes (ISGs). ISGs can inhibit multiple steps of the viral life cycle (e.g. entry, protein translation, 
assembly, or egress) or modulate the immune response, such as by enhancing the recruitment of 
leukocytes or promoting B and T cell maturation (14). 
IFN-induced transmembrane (IFITM) proteins 1, 2 and 3 were among the first IFN-
stimulated genes (ISGs) to be identified (92), and initially were studied for their roles in germ 
cell homing and maturation. IFITM proteins are approximately 130 amino acids in length, and 
are conserved in most vertebrate species (93). IFITMs have no catalytic subunit, but share 
similar domain architectures consisting of a short N-terminal domain, two antiparallel domains, a 
conserved intracellular loop, and a hydrophobic C-terminal domain (94, 95). The topology of 
IFITM3 has been clarified by electron paramagnetic and nuclear magnetic resonance analyses; 
the N-terminal is located inside the cell, whereas the antiparallel domains reside as 
intramembrane α-helices, followed by the transmembrane C-terminal domain (96). Although 
IFITM1, 2, and 3 all have reported antiviral activity, IFITM3 exhibits the greatest protection 
against the broadest range of viruses including influenza A virus (IAV), flaviviruses (Dengue, 
West Nile, and Japanese encephalitis viruses), hepaciviruses (hepatitis C virus), filoviruses 
(Ebola and Marburg viruses), bunyaviruses (Rift Valley Fever and La Crosse viruses), 
rhabdoviruses (vesicular stomatitis virus), coronaviruses (SARS-CoV), paramyxoviruses 
(respiratory syncytial virus, RSV), and reoviruses (9, 56, 60, 61, 64, 66, 68–70, 97, 98). Despite 
a wealth of in vitro data, the antiviral effects of IFITM3 in vivo are less well characterized. To 
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date, only IAV and RSV have been shown to have enhanced pathogenesis in Ifitm3-deficient 
(Ifitm3-/-) mice (59, 63, 64). In humans, the allelic polymorphism rs12252-C, which results in a 
splice variant of IFITM3 lacking the first 21 amino-terminal amino acids, correlates with 
increased morbidity and mortality following IAV infection (63, 99, 100). However, some studies 
have questioned the significance of this truncated IFITM3 allele in the susceptibility to IAV and 
other viral infections (80, 81). 
 The mechanisms by which IFITM3 restrict viral infection are not fully elucidated. 
Studies have shown that IFITM3 affects pH dependent fusion in the late endosome, which 
potentially traps entering virions in a hemifusion state (57, 78, 101). IFITM3 expression also can 
modulate the efficiency of cathepsin-mediated proteolysis in an as yet undefined manner, which 
is required for the cleavage of the fusion proteins of reoviruses, filoviruses, and coronaviruses, 
and release of the viral genome from the endolysosome into the cytosol (56, 69). Additionally, 
IFITM3 is incorporated into the plasma membrane of budding HIV particles, which restricts their 
fusogenic capability (72). Finally, ectopic expression of IFITMs appears to alter the physical 
characteristics of the endosome, resulting in increased size, reduced membrane fluidity, and 
increased cholesterol content, which subsequently impact the efficiency of viral fusion (52, 78, 
79). 
 Alphaviruses are enveloped single-stranded positive sense RNA viruses of the 
Togaviridae family, many of which are transmitted by mosquitoes. The binding, entry, and pH-
dependent fusion of alphaviruses are directed by the structural glycoproteins E1 and E2 (102, 
103). E1 and E2 are arranged as heterodimers, and assembled into trimeric spikes on the surface 
of the virion (104). E1 is classified as a type II membrane fusion protein, whereas E2 contains 
the putative receptor binding site (102).  
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Chikungunya virus (CHIKV) has emerged rapidly over the last decade, causing outbreaks 
in the islands of the Indian Ocean, in Southern Europe, and in Southeast Asia. In 2013, CHIKV 
spread to the Western Hemisphere and by the end of 2015 had infected more than 1.8 million 
people in North, Central, and South America (30). Other arthritogenic alphaviruses have a more 
limited distribution in parts of Oceania, Africa, and South America, whereas outbreaks of 
encephalitic alphaviruses occur sporadically in North, Central, and South America (105). 
Infection by arthritogenic alphaviruses, including CHIKV, Sindbis, Ross River, and Mayaro 
viruses, results in a febrile illness associated with rash, myalgia, and moderate to severe joint 
pain (41). The musculoskeletal disease caused by these viruses is associated with direct infection 
of myocytes, synovial fibroblasts and osteoblasts (32, 34, 38, 39, 41) and the ensuing infiltration 
of inflammatory cells. Infection by encephalitic alphaviruses, including Venezuelan (VEEV), 
Eastern, and Western equine encephalitis viruses, causes a severe febrile illness associated with 
infection and injury to neurons, encephalitis, long-term debilitating neurological sequelae, and 
death (105). To date, there are no licensed alphavirus vaccines available for use in humans. 
 Several ISGs have been characterized as restriction factors against alphavirus infection, 
including ISG15, PKR, ZAP and BST-2; these genes target viral protein translation and virion 
egress, respectively (15–17, 19, 46). Ectopic expression-based screens against alphaviruses also 
have revealed putative inhibitory genes, including Isg20, Ifit1, Ifit2, Ifit3, and Rsad2 (47). 
However, in the case of Ifit1, which recognizes RNA lacking a 2'-O methylation on the 5' cap 
structure and prevents translation, alphaviruses subvert its antiviral function via RNA secondary 
structure motifs that inhibit binding (48). Recent studies suggest that ectopic expression of 
IFITM genes in cell culture can restrict infection of Sindbis (SINV) and Semliki Forest (SFV) 
viruses in cell culture by inhibiting viral fusion with cellular membranes (106). Other ISGs (e.g., 
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HSPE and P2RY6), have been identified, with little information regarding their mechanism of 
restriction (7, 20). Finally, ISGs can act in synergy to inhibit alphavirus infection (45).  
 In this study, we evaluated the antiviral activity of IFITM3 against several alphaviruses 
by comparing infection of IFN-treated wild-type (WT), Ifitm3-/-, and Ifitm locus deletion (Ifitm-
del) mouse fibroblasts with CHIKV, SFV, SINV, O'nyong nyong (ONNV), and VEEV viruses. 
In the absence of Ifitm3 gene expression we observed an increase in alphavirus replication in 
vitro, which was inhibited following trans-complementation with Ifitm3. In vivo, Ifitm3-/- mice 
inoculated with CHIKV sustained higher viral burden in the spleen, serum, and joint tissues at 
early times after infection. This was associated with higher levels of pro-inflammatory cytokines 
and increased joint swelling along with greater replication in macrophages in some tissues. 
Consistent with this latter observation, bone marrow derived macrophages from Ifitm3-/- mice 
sustained higher levels of CHIKV infection than WT cells. Analogous to our observed 
phenotypes with CHIKV in vivo, Ifitm3-/- mice infected with VEEV exhibited greater weight loss 
and mortality, and supported greater replication in the liver, spleen, spinal cord, and brain. 
Collectively, our data suggest that Ifitm3 contributes to an early host defense response against 
multiple alphaviruses of global concern.   
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MATERIALS AND METHODS 
Ethics statement. This study was carried out in accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocols were approved by the Institutional Animal Care and Use Committee at the Washington 
University School of Medicine (Assurance Number: A3381-01). Dissections and injections were 
performed under anesthesia that was induced with ketamine hydrochloride and xylazine.  
 Mice. WT C57BL/6 mice were obtained commercially from Jackson Laboratories. Ifitm-
del and Ifitm3-/- mice have been reported previously (107). Ifitm2-/- mice will be described in a 
forthcoming manuscript (M. Gorman and M. Diamond, unpublished data). All transgenic mice 
were backcrossed to 99% purity using speed congenic analysis (108). Four week-old mice were 
inoculated in the left footpad with 103 FFU of CHIKV-LR in 10 µl of PBS. Ankles were 
measured (width x height) for joint swelling on days 3 and 7 post infection. On selected days 
after infection, mice were sacrificed for the collection of serum and tissues. After intracardiac 
perfusion with PBS, organs were harvested, weighed and homogenized to determine viral titers 
by a focus forming assay. For studies with VEEV, a vaccine-derived recombinant strain with a 
point mutation (TC83-A3G) was used; this mutation confers partial virulence in WT mice as it 
restores the capacity to antagonize the inhibitory actions of the ISG, Ifit1 (48). Four week-old 
mice were inoculated in the left footpad with 106 FFU of VEEV-TC83-A3G in 10 µl of PBS. 
Mice were followed daily for survival and weighed every two days. On selected days, infected 
mice were sacrificed and organs were harvested as described above. 
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 Flow cytometric analysis of CHIKV-infected splenocytes. Spleens of CHIKV-infected 
mice were harvested after perfusion with PBS. Splenocytes were obtained by generating a single 
cell suspension, passaging through a 70 µm filter, and lysis of red blood cells with ACK buffer 
(Invitrogen). Splenocytes were maintained on ice in PBS supplemented with 2% FBS and 1 mM 
EDTA. After blockade of Fcγ receptors with anti-CD16/32 (eBioscience Clone 93), staining for 
viability (eBioscience FVD eFluor 506), and cell surface antigens CD45, CD3, CD19, CD3, 
Ly6G, Ly6C, CD11b, CD11c, MHC class II, and F4/80 was performed. Viral antigen (E1 and E2 
proteins on the surface of cells) was detected using biotinylated humanized CHK-152 and 
murine CHK-166 (37), with biotinylated humanized WNV E16 and murine WNV E60 (109, 
110) serving as isotype controls, respectively. Secondary staining was followed with streptavidin 
conjugated Alexa 647 (Invitrogen). Cells were fixed subsequently using the eBioscience FoxP3 
Fixation Buffer Set and processed for flow cytometry with the BD LSRII. Data were analyzed 
with FloJo software. 
Bioplex cytokine assay. To measure cytokine levels, a BioPlex Pro Assay was 
performed according to the manufacturer's protocol (BioRad) on homogenized ankle tissues 
isolated at day 1 and 2 post infection. The cytokine screen included IL-1α, IL-1β, IL-2, IL-3 IL-
4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, 
KC, MCP-1 MIP-1α, MIP-1β, RANTES (CCL5), and TNF-α. 
 Cells and viruses. Primary WT, Ifitm-del, Ifitm2-/- and Ifitm3-/- derived mouse embryonic 
fibroblasts (MEFs) and bone marrow derived macrophages were generated according to 
published methods (111). Transformed MEFs were generated by transfection of the SV2 
plasmid, which encodes for the large T antigen of SV2 polyoma virus (112), and passaged ~10 
times. All MEFs were cultured in complete DMEM, which was supplemented with 10% fetal 
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bovine serum, and 10 mM each of GlutaMAX, sodium pyruvate, non-essential amino acids and 
HEPES pH 7.3. MEFs that ectopically express c-Myc-tagged firefly luciferase or c-Myc-tagged 
Ifitm3 were generated via lentiviral transduction of the pFCIV vector, which contains an IRES-
GFP (113, 114). Lentivirus was produced by transfecting 293T cells with pSPAX.2 (Addgene 
12260), pMD2G (Addgene 12259) and pFCIV. Supernatants were harvested at 48 to 72 h post 
transfection. WT, Ifitm-del and Ifitm3-/- transformed MEFs were incubated with lentiviral 
supernatants and 10 µg/ml of polybrene and spinoculated (300 x g) at room temperature for 30 
min. The inoculum was replaced with complete DMEM 24 h later and incubated at 37°C. 
Transduction efficiency was determined by expression of GFP, and sorting of GFP+ cells was 
performed on a FACS AriaII (Becton-Dickinson). After repeated passages to ensure stable 
expression, the MEFs were tested for GFP and protein expression by flow cytometry and 
Western blotting, respectively. Vero and 293T cells were cultured and passaged in complete 
DMEM. 
 The CHIKV-LR (La Reunion OPY1 p142) strain was a gift from S. Higgs (Kansas State 
University). SINV (Toto) was a gift from C. Rice and P. MacDonald (Rockefeller University). 
VEEV-TC83 was a gift from W. Klimstra (University of Pittsburgh). These strains were 
produced from infectious cDNA clones (115, 116). CHIKV 181/25, ONNV (MP30), SFV 
(Kumba), were provided by the World Reference Center for Arboviruses (R. Tesh, University of 
Texas Medical Branch).  Virus propagation and titration was performed in Vero cells.  
 Genotyping of MEFs. Genomic DNA was extracted from MEFs with the Qiagen 
DNeasy Blood and Tissue kit, and was characterized by PCR. Ifitm2 WT allele or the knockout 
construct was genotyped using the following primers: Ifitm2 WT F: 5'-
ATGTGGTCTGGTCCCTGTTC-3', Ifitm2 WT R: 5'-AGGTGCTCTGGCTCCATTTC-3'; WT 
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band = 520 bp. Ifitm2 KO F: 5'-TCATTCTCAGTATTGTTTTGCC-3', Ifitm2 KO R: 5'-
TGGAGACCAGAAGCCTGAC-3';  KO band = 373 bp. PCR reaction conditions for both Ifitm2 
WT and KO alleles were as follows: 94°C for 3 min, 94°C for 45 s,  55°C for 30 s, 70°C for 1 
min 30 s, 35 cycles, and  70°C for 10 min. The Ifitm3-/- mouse can be identified by the in-frame 
insertion of GFP within the Ifitm3 allele (C Bailey, unpublished)(107).  WT allele or the 
knockout construct was genotyped using the following primers:  WT Ifitm3 F: 5'-
ATCCTTTGCCCTTCAGTGCT-3' and WT Ifitm3 R: 5'-ACTCATACCTCGGTGCCATC-3'; 
WT band = 355 bp, KO band = 1321 bp. PCR reaction conditions for both Ifitm3 WT and KO 
were as follows: (a) 94°C for 1 min 30 s, 94°C for 25 s, 60°C for 30 s, reducing temperature by 
0.1°C per cycle, 72°C for 1 min 30 s, 35 cycles, and 72°C for 5 min. The IFITM-del allele was 
determined using the following primers (107): IFITM-del WT F: 5'-
AACATGCCTTGCATCCCTGGAGTTCCTTCTAAAGGA-3', IFITM-del WT R: 5'-
CCCTAAAACACTTAGCAGTGACCCCTCACAAGCC-3'; WT band = 500bp. Ifitm-del KO F: 
5'-ACTCTAGCCAGAGTCTTGCATTTCTCAGTCCTAAAC-3', IFITM-del KO R: 5'-
TCTAGTACAGTCGGTAAGAACAAAATAGTGTCTATC A-3'; KO band = 600bp. PCR 
reaction conditions for Ifitm-del alleles were as follows: 95°C for 30 s, 54°C for 30 s, 68°C for 1 
min 30 s, 29 cycles, and 68°C for 5 min.  
 qRT-PCR measurement of Ifitm genes. WT, Ifitm2-/-, Ifitm3-/- and Ifitm-del MEFs (104 
cells per condition) were seeded in a 96-well plate. After a 6 h incubation with IFN-β at varying 
doses, MEFs were lysed and total RNA was extracted with the Qiagen RNeasy Kit. Ifitm2 and 
Ifitm3 were detected using qRT-PCR and normalized to Gapdh expression, using the following 
PrimeTime assays (IDT) according to the manufacturer’s instructions: Ifitm2: 
Mm.PT.58.33172327.g, Ifitm3: Mm.PT.51.6979575.g, and Gapdh: Mm.PT.39a.a. 
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 Western blotting. MEFs were lysed in RIPA and electrophoresed under reducing 
conditions on a 12% Bis-Tris NuPAGE gel with MES buffer according to the manufacturer’s 
instructions (Thermo Fisher). After transfer onto PVDF membranes (Thermo Fisher) using an 
iBlot apparatus (Thermo Fisher), proteins of interest were detected with mouse anti-b-actin 
(CST, 8H10D10), mouse anti-c-Myc (Sigma, 9E10), goat anti-Ifitm3 (R & D, AF337), HRP-
conjugated anti-mouse IgG (Sigma Chemical), and HRP-conjugated anti-goat IgG (Santa Cruz, 
sc2304). For quantification of protein, secondary donkey anti-mouse IRDye 680 (Li-Cor 925-
68072) and anti-rabbit- IRDye 800CW (Li-Cor, 926-32214) were used instead of HRP 
conjugates, and visualized on the Odyssey Imager (Li-Cor). Polyclonal rabbit anti-Ifitm3 
(Proteintech, 11714-1-AP) was used for Ifitm3 detection in these experiments. Quantification 
was performed with Li-Cor Odyssey software. 
 Virus infection of cells. MEFs were plated (104 cells per well) in a 96-well plate, and in 
some experiments pretreated for 6 h with recombinant mouse IFNβ (PBL Assay Science) at 
concentrations from 5 to 0.1 IU/ml, as indicated in the Figure Legends. The cells were inoculated 
with a given alphavirus (multiplicity of infection (MOI) of 5) and incubated at 37°C. At selected 
time points, cells were trypsinized, fixed with 1% paraformaldehyde (PFA), and permeabilized 
with Hank’s Balanced salt solution (HBSS) containing 0.1% saponin and 10 mM HEPES. 
Infection was determined after sequentially staining cells with mouse or human mAbs (CHIKV, 
CHK-11; SFV, 2B4; TC83, 1A4A-1; ONNV, 4J21) (37, 117) against the E2 glycoprotein. SINV 
infection was detected using murine anti-SINV ascites (ATCC, VR-1248AF). Alexa 647 
conjugated goat-anti mouse or human IgG antibody (Life Technologies) was used for secondary 
antibody staining. Samples were processed by flow cytometry using a BD FACSArray. Data 
were analyzed with FloJo software. 
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  For viral yield assays, cells were plated (105 cells per well in a 12-well plate) and in some 
experiments pretreated with specified doses of IFNβ for 12 hours. Cells then were infected with 
CHIKV at 37°C. One hour later, the plates were rinsed twice with warm PBS, and replaced with 
fresh DMEM supplemented with 10% FBS. Supernatants were collected at specific time points, 
and viral titers were determined by focus forming assay on Vero cells, as described (37, 48). 
After fixation, infected cell foci were detected with CHK-11 and HRP-conjugated anti-mouse 
IgG (Sigma Chemical), and quantified with an ImmunoSpot (Cellular Technologies, Ltd.). 
 Binding and internalization assays. MEFs were plated (105 cells/well in a 24 well plate) 
the night before use. Cells were chilled on ice for 10 min, exposed to CHIKV-LR at an MOI of 
5, and incubated on ice for 1 h. Unbound virus was removed with repeated washes of chilled 
media or PBS. To determine binding efficiency of virus, MEFs were lysed with RLT buffer and 
RNA was extracted using the Qiagen RNeasy Mini Kit, and analyzed for CHIKV RNA by qRT-
PCR. To determine the efficiency of virus internalization, warm complete DMEM was added to 
MEFs and incubated at 37°C for 1 hr. Medium was removed and cells were placed on ice. 
Proteinase K (500 µg/ml) in ice cold PBS was added for 1 h to digest any surface bound virus 
(118). MEFs were then transferred to eppendorf tubes and washed with PBS before lysing with 
RLT buffer and extracting RNA for qRT-PCR. Primer probe sets were ordered from IDT were 
CHIKV (F: 5'-TCGACGCGCCCTCTTTAA-3', R: 5'-ATCGAATGCACCGCACACT-3', Probe: 
5'-/56-FAM/ACCAGCCTGCACCCATTCCTCAGAC/36-TAMSp/-3') and the GAPDH 
Primetime Assay Mm.PT.39a.a. 
 Fusion from without (FFWO) assay. MEFs were rinsed and then incubated with 
DMEM, supplemented with 0.2% FBS, 10 mM HEPES pH 7.3 and 20 mM NH4Cl on ice for 15 
min. Virus (MOI of 100) was added to MEFs on ice for one hour to allow binding. Unbound 
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virus was removed after several rinses with chilled medium. Subsequently, pre-warmed acidic 
(DMEM, 0.2% FBS, 10 mM HEPES, 30 mM succinic acid pH 5.5) or neutral (DMEM, 0.2% 
FBS, 10 mM HEPES, pH 7.4) medium was added for 2 min at 37°C. Medium then was removed 
and replaced with warmed DMEM, 10% FBS, 10 mM HEPES supplemented with 20 mM NH4Cl 
to inhibit endosomal viral fusion and de novo infection via the endosomal pathway. At 6 h after 
infection, MEFs were fixed with PFA, permeabilized, and analyzed for viral antigen by flow 
cytometry, as described above. 
 Statistical analysis. All data was analyzed using Prism software (GraphPad6, San Diego, 
CA). Viral infection assays in cell culture were analyzed by one-way ANOVA with Dunnett’s 
multiple comparisons test, or Student’s t-test. Viral kinetics assays were analyzed by two-way 
ANOVA with Dunnett’s or Sidak’s multiple comparisons. Viral burden assays were analyzed by 
the Mann-Whitney test. Quantitative RT-PCR assays were analyzed by Student’s t-test. Kaplan-
Meier survival curves were analyzed by the log rank test.  
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RESULTS 
Restriction of alphaviruses by Ifitm proteins in cell culture. Although expression of 
IFITM genes inhibits infection of several different genera of viruses (9, 56, 60, 61, 64, 66, 68–
70, 97), their antiviral activities against alphaviruses have yet to be established. To test whether 
Ifitm genes restrict alphavirus infection, we developed MEF lines lacking Ifitm2 (Ifitm2-/-), 
Ifitm3 (Ifitm3-/-), and Ifitm1, 2, 3, 5, and 6 (Ifitm-del) (Fig 3.1A). To assess their effects on 
CHIKV replication, MEFs were first pretreated with 1 IU/ml of recombinant mouse IFNβ to 
induce Ifitm gene expression (Fig 3.1B). Ifitm3 protein induction was confirmed by Western 
blotting in WT and Ifitm2-/- MEFs after IFNβ treatment, whereas, as expected, Ifitm3-/- and Ifitm-
del MEFs lacked Ifitm3 protein (Fig 3.1C). IFN pretreated MEFs were then infected with a high 
viral dose (MOI of 5) of pathogenic (CHIKV-La Reunion 2006 (LR)) or attenuated (CHIKV 
181/25) strains of CHIKV. Fourteen hours later, cells were harvested, and viral antigen was 
analyzed by flow cytometry. Whereas Ifitm3-/- and Ifitm-del MEFs supported greater CHIKV 
infection (3-fold, P < 0.01 and 4-fold, P < 0.001 for CHIKV 181/25; 4.5-fold, P < 0.0001 and 
6.5-fold, P < 0.0001 for CHIKV-LR) than WT cells, no increase in viral antigen expression was 
observed in Ifitm2-/- MEFs (Fig 3.1D-F). Correspondingly, IFNβ pre-treated Ifitm3-/- and Ifitm-
del MEFs infected with CHIKV produced higher titers of infectious virus compared to WT or 
Ifitm2-/- cells (Fig 3.1G, CHIKV 181/25: 28-fold for Ifitm3-/- (P < 0.01), and 12-fold for Ifitm-del 
(P < 0.05); Fig 3.1H, CHIKV-LR: 147-fold for Ifitm3-/- (P < 0.0001), and 36-fold for Ifitm-del 
(P < 0.0001)) at 14 h post-infection. These data suggest that Ifitm3 has a dominant antiviral 
effect on CHIKV infection compared to Ifitm2. 
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We next tested whether Ifitm3 exhibited antiviral activity against other alphaviruses. 
Analogous to experiments with CHIKV, WT and Ifitm-deficient MEFs were pre-treated with 
varying doses of IFNβ, infected at a high MOI, and assayed by flow cytometry. Notably, Ifitm3-/- 
and Ifitm-del MEFs pre-treated with IFNβ supported enhanced infection by SFV, ONNV, VEEV 
(strain TC-83), and SINV compared to WT cells (P < 0.05, Fig 3.2).  
To corroborate our findings, we trans-complemented WT, Ifitm3-/- and Ifitm-del MEFs 
with c-myc tagged to the N-terminal of Ifitm3 or firefly luciferase protein as a control. After 
confirmation of ectopic protein expression by flow cytometry and Western blotting (Fig 3.3A 
and B), MEFs were infected with CHIKV 181/25 (MOI of 5) in the absence of IFNβ treatment 
and analyzed at 6 h post-infection. MEFs trans-complemented with Ifitm3 showed less CHIKV 
replication than firefly luciferase expressing controls (Fig 3.3C and D). This data suggests that 
Ifitm3 inhibits multiple alphaviruses in vitro and does not require expression of Ifitm1, Ifitm2, 
Ifitm5, and Ifitm6 proteins to exert its antiviral activity. 
Ifitm3 inhibits pH-dependent fusion of alphaviruses. Studies with IAV have shown 
that IFITM3 prevents fusion of virions from the late endosome, which is required for release of 
viral genomic material into the cytosol (57, 101). Correspondingly, IFITM3 is expressed 
preferentially on membranes of intracellular vesicles including endosomes (56). However, 
following gene upregulation, such as after IFN induction or ectopic expression, IFITM3 can 
accumulate on the plasma membrane (59, 62, 119), which independently could restrict 
attachment of viruses to the cell surface. To define the stage in the alphavirus lifecycle that 
Ifitm3 inhibits, we assessed its effect on binding, internalization, and fusion. 
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To determine if expression of Ifitm3 alters binding of alphaviruses to the cell surface, 
trans-complemented MEFs were incubated with CHIKV at 4°C for 1 h, washed extensively to 
remove unbound virus, and assayed by quantitative RT-PCR (qRT-PCR). As no differences in 
levels of bound CHIKV genomic RNA were detected between Ifitm3 expressing MEFs and their 
corresponding controls (Fig 3.4A), we concluded that binding efficiency was not appreciably 
affected. To assess whether Ifitm3 affected internalization, CHIKV was pre-bound to trans-
complemented MEFs for 1 h on ice, followed by incubation at 37°C for 1 h. MEFs then were 
treated with proteinase K to remove residual surface bound virus before recovery of cellular 
RNA. Similar to cell surface binding assays, we observed no difference in the levels of 
internalized viral RNA (Fig 3.4B). As anticipated, in control binding experiments performed at 
4oC, proteinase K treatment significantly decreased (11-fold, P < 0.0001) the level of cell-bound 
viral RNA (Fig 3.4C). 
As we did not observe effects of Ifitm3 on attachment or internalization, we next 
evaluated pH-dependent fusion. Alphaviruses can be induced to fuse at the plasma membrane in 
the presence of an acidic solution (acid-bypass or fusion from without (FFWO)) (120), albeit at 
low efficiency; this required us to infect at a high multiplicity of infection. To test whether 
FFWO is affected by ectopic expression of Ifitm3, MEFs were pre-incubated with CHIKV at 
4°C, washed to remove unbound virus, and then incubated with pre-warmed medium at pH 7.4 
or pH 5.5. Subsequently, medium was replaced with normal pH culture medium supplemented 
with 20 mM NH4Cl, which prevents alphavirus maturation and fusion (120), was added to inhibit 
productive infection of progeny virions. Fourteen hours later, MEFs were analyzed for viral 
antigen by flow cytometry. Ifitm3 trans-complemented MEFs had lower levels of CHIKV 
antigen than luciferase expressing controls in WT, Ifitm3-/- and Ifitm-del MEFs (Fig 3.4D and 
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E). Consistent with results with IAV (101), expression of Ifitm3 also inhibits pH-dependent 
fusion of alphaviruses. 
Ifitm3 inhibits alphavirus infection in vivo. To determine whether Ifitm3 has a 
protective role against alphaviruses in vivo, we used an established mouse model of CHIKV 
infection and arthritis (36). We inoculated 4-week old WT and Ifitm3-/- mice with CHIKV-LR in 
the left footpad and measured joint swelling on days 3 and 7 after infection, which correspond to 
the peaks of tissue edema and cellular infiltrates, respectively (36, 37). Whereas no difference 
was seen in viral titers at these time points (Fig 3.5A), greater swelling was observed in 
ipsilateral ankle joints of Ifitm3-/- compared to WT mice on both days, (Fig 3.5B and C, P < 
0.001 and P < 0.01). Because of the disparity between clinical signs and virological data, we 
analyzed viral burden in different tissues (serum, spleen, ankles, wrists, and quadriceps muscles) 
at earlier time points (days 1 and 2 after inoculation) (Fig 3.5D-K). At day 1 after inoculation, 
the serum, spleen, and ipsilateral ankle (Fig 3.5D-F) of Ifitm3-/- mice had higher viral titers 
compared to WT mice (20-fold in serum P  < 0.0001; 160-fold in spleen, P < 0.0001; and 2.5-
fold in ipsilateral ankle, P < 0.01). In comparison, at day 2, the titers in the spleen, serum and 
ipsilateral ankle were similar but levels in the contralateral ankle and quadriceps muscle (Fig 
3.5G and I) were somewhat higher (4.5-fold, P < 0.001; and 5-fold P < 0.01, respectively). 
However, by day 3, no differences in viral titer were observed in any tissues between WT and 
Ifitm3-/- mice.  
The early higher viral burden in Ifitm3-/- mice corresponded to higher levels of 
inflammatory chemokines and cytokines in the ipsilateral ankle (Table 3.1). The mean 
concentrations of several chemokines and cytokines (e.g., IL-2, MCP-1, TNF-α, IL-1α, IL-
12p40, G-CSF, and GM-CSF, P < 0.05) were higher in ankles from CHIKV-infected Ifitm3-/- 
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than WT mice at days 1 and/or and 2 after infection. These data suggest that in the context of 
CHIKV infection in vivo, Ifitm3 contributes to restriction of early viral infection and spread, 
which impacts cytokine induction and the development of clinical disease. 
Given the increase in viral titers in the spleen of Ifitm3-/- mice on day 1, we hypothesized 
that Ifitm3 might affect the cellular tropism of CHIKV. To identify the cell subsets that were 
more susceptible to CHIKV infection, we performed flow cytometric analysis on spleens of 
infected WT and Ifitm3-/- mice (Fig 3.6A-C). Splenocytes were stained for CHIKV envelope (E1 
and E2) proteins using specific MAbs (37) and compared to isotype control MAbs. Inflammatory 
monocytes (CD11b+Ly6G+), macrophages (CD11bhiF4/80lo), and red pulp macrophages 
(CD11bloF4/80hi) expressed high levels of viral antigen (50%, 50% and 25%, respectively), with 
no difference in the fraction of infected cells from WT and Ifitm3-/- cells (Fig 3.6B and data not 
shown). Nonetheless, greater numbers of CHIKV antigen-positive CD11bhiF4/80lo and 
CD11bloF4/80hi macrophages were detected in the spleens of Ifitm3-/- compared to WT mice (1.3 
fold, P < 0.05; 1.7 fold, P < 0.05; and 2.2 fold, P < 0.05, respectively; Fig 3.6C). An increased 
number of Ifitm3-/- neutrophils expressed CHIKV antigen (1.6 fold, P < 0.05), but the overall 
number of neutrophils was substantially lower compared to other myeloid cell populations. No 
differences in viral antigen-positive inflammatory monocytes were observed between the Ifitm3-/- 
and WT controls, and neither Ifitm3-/- nor WT CD4+, CD8+, CD19+, or NK1.1+ cells exhibited 
detectable viral protein staining (data not shown). To determine if Ifitm3-/- macrophages can 
support greater replication of CHIKV, bone marrow derived macrophages were cultured from 
WT and Ifitm3-/- mice, and infected at an MOI of 0.1. Viral supernatants were collected up to 72 
h post infection and analyzed by focus forming assay. Ifitm3-/- macrophages produced more virus 
at 24 and 48 h post infection compared to WT cells (Fig 3.6D, 12.5-fold, P < 0.01 and 10-fold, P 
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< 0.01, respectively). These data suggest that a lack of Ifitm3 allows for enhanced CHIKV 
infection in macrophages. 
To assess whether Ifitm3 had a protective effect against other alphaviruses in vivo, we 
infected 4 week-old WT and Ifitm3-/- mice with a previously described moderately pathogenic 
encephalitic alphavirus strain (VEEV TC83-A3G), which is resistant to the antiviral effects of 
another ISG, Ifit1 (48). Ifitm3-/- mice exhibited greater mortality (Fig 3.7A) and morbidity (as 
judged by weight loss, Fig 3.7B) after VEEV TC83-A3G infection compared to WT mice. 
Consistent with the clinical phenotypes, higher VEEV titers were observed at day 1 after 
infection in the liver and spinal cord (3-fold, P < 0.05; 8-fold, P < 0.01, respectively, Fig 3.7C) 
and day 2 after infection in the spleen, brain, and liver of Ifitm3-/- compared to WT mice (2.5-
fold, P < 0.05; 250-fold, P < 0.05; and 10-fold, P < 0.01, respectively, Fig 3.7C). These data 
confirm that Ifitm3 restricts alphavirus infection in vivo and prevent early dissemination. 
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DISCUSSION 
To evaluate the potential antiviral role of Ifitm3 in restricting alphaviruses in vitro, we 
infected WT, Ifitm3-/- and Ifitm-del MEFs with CHIKV, SFV, ONNV, VEEV and SINV. All 
alphaviruses tested exhibited some degree of enhanced infection in Ifitm3-/- cells. In contrast, 
studies with CHIKV and Ifitm2-/- MEFs showed comparable infection to WT MEFs, suggesting 
that Ifitm2 is not the predominant Ifitm gene responsible for the inhibiting alphaviruses in the 
context of an intact type I IFN response. The antiviral function of Ifitm3 against alphaviruses 
was validated using trans-complemented MEFs that ectopically express Ifitm3. Analogous to 
how IFITM3 inhibits IAV infection (78, 101), our mechanism of action studies suggest that 
Ifitm3 does not affect the binding or internalization of CHIKV, but instead prevents pH-
dependent fusion events.  
We also observed greater CHIKV infection and disease pathogenesis in vivo in animals 
lacking Ifitm3 expression. Ifitm3-/- mice developed greater ankle swelling compared to WT 
animals, and this difference correlated with an increased in viral burden and inflammatory 
chemokine and cytokine levels at early times post inoculation. Notably, at later time points, titers 
became equivalent in WT and Ifitm3-/- mice, suggesting possible immune evasion of Ifitm3 by 
CHIKV, which could occur by several previously identified mechanisms including host 
transcriptional shut-off (121) or antagonism of IFN signaling (122). To assess possible effects of 
Ifitm3 on cellular tropism, we assessed CHIKV antigen staining using flow cytometric analysis 
of splenocytes at day 1 post infection. These cells were chosen because they were easily profiled, 
and exhibited substantial (160-fold) difference in viral yield at this time point. Although the 
overall percentage of CHIKV-positive myeloid cells was similar in the spleens of Ifitm3-/- and 
WT mice, a higher number of macrophages were positive for CHIKV antigen, suggesting a 
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possible role for Ifitm3 in controlling viral growth in these cell types. One limitation of the flow 
cytometry experiments is that we cannot be certain that CHIKV antigen-positive staining defines 
bona fide infection, as it remains possible that we are detecting bound/opsonized virus on the 
surface of cells rather than E1 and E2 proteins prior to budding. To address this issue, we tried 
infection studies in WT and Ifitm3-/- mice with double subgenomic reporter gene viruses (e.g., 
CHIKV-GFP); however the fluorescence staining was too dim for conclusive results, possibly 
because of the attenuation of these viruses. Nonetheless, our studies with bone marrow derived 
macrophages support a role for Ifitm3 restriction of CHIKV infection in this cell type, as 
increased titers were observed in cells from Ifitm3-/- mice. 
Our in vivo findings were not limited to CHIKV, as we also observed greater mortality, 
weight loss, and viral burden following VEEV infection of Ifitm3-/- mice. These data suggest an 
important role for Ifitm3 in restricting alphavirus pathogenesis in vivo, by limiting replication 
and dissemination early during infection. Future studies using analogous flow cytometric 
approaches and conditional gene deletions are planned to define the cell-type specific antiviral 
effect of Ifitm3 in the context of VEEV pathogenesis. 
A possible antiviral role of IFITM proteins against alphaviruses has not been extensively 
analyzed. Studies with pseudotyped virions (alphavirus structural proteins and retroviral RNA) 
initially suggested that IFITMs had little antiviral activity against CHIKV, SINV, and VEEV (M. 
Farzan, unpublished observations (52)). It remains uncertain why Ifitm3 would not inhibit 
pseudotyped alphavirus virions although the icosahedral display of E1 and E2 may be altered in 
these viruses, which could affect entry and fusion of virus particles. Ifitm3 has been implicated 
although not definitively demonstrated as a restriction factor for alphaviruses. Karki et al 
identified IFITM3 as one of 31 human ISGs that functioned synergistically with zinc finger 
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antiviral protein (ZAP) to enhance restriction of SINV infection (45). Schoggins et al reported 
that IFITM3 moderately reduced CHIKV and ONNV  infection  in human cells ectopically 
expressing IFITM3 (20, 84). Consistent with these observations, a recent paper reported an 
inhibitory effect of IFITM3 and IFITM1 against SFV and SINV when ectopically expressed in 
human A549 cells  (106). These data support our findings of an antiviral activity of Ifitm3 
against multiple alphaviruses.  
The characterization of Ifitm3 as an antiviral ISG against alphaviruses adds to the known 
host defense genes that block alphavirus infection. ISG15 protects against SINV in vivo, likely 
via conjugation (ISGylation) to viral proteins (15–17), ZAP restricts SINV, Ross River, SFV, 
and VEEV by blocking the accumulation of viral genomic content in the cytoplasm (8), and 
BST-2 (tetherin) prevents CHIKV egress by retaining budding virus on the plasma membrane 
(19). SINV also is strongly inhibited by PKR in the context of replication in DCs (46). Finally, a 
separate genetic screen revealed several unique ISGs with possible antiviral activity, against 
SINV including Isg20, Ifit1, Ifit2, Ifit3, and Rsad2 (viperin) (47).  
 In studies with other viruses, IFITM3 appears to restrict early steps in the viral lifecycle, 
particularly fusion into the cytoplasm (57, 78, 101). This is supported by data from our FFWO 
experiments in the context of CHIKV infection and by recent studies with SFV (106). However, 
it remains possible that IFITM3, akin to effects on HIV, could restrict alphavirus infection in a 
pH insensitive manner by integrating into the viral membrane, which we are currently exploring 
using mass spectrometric analysis of alphavirus virions derived from cells expressing or lacking 
Ifitm3. An additional mechanism that warrants investigation is the possible role for Ifitm3 in 
preventing viral budding and/or egress. IFITM3 can be detected at the plasma membrane, and its 
expression and localization is enhanced upon IFN stimulation (59, 62, 119). 
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 In summary, we have shown that Ifitm3 can restrict several alphaviruses both in vitro and 
in vivo. Our data in mice suggest that Ifitm3 may function to restrict early replication and 
dissemination of alphaviruses, thereby preventing pathogenesis. Further investigation into 
additional mechanisms of Ifitm3 mediated restriction of alphaviruses is warranted as well as 
effects of gene polymorphisms, which could contribute to relative disease susceptibility in 
humans. Indeed, a common human allelic IFITM3 variant, rs12252-C, encodes for a 21 amino 
acid deletion of the N terminal part of the protein that appears to be associated with susceptibility 
to IAV infection (63, 99, 100). It remains to be determined whether this or other polymorphisms 
in the IFITM3 gene can be linked to more severe or persistent alphavirus infection. 
 
	  	   82	  
Figure 3.1  
 
 
Figure 3.1. CHIKV infection is enhanced in cells lacking Ifitm3 expression. 
WT, Ifitm2−/−, Ifitm3−/−, and Ifitm-del MEFs were generated from WT and gene-targeted mice. 
(A) Genotyping of MEFs was performed by PCR and agarose electrophoresis. Bands 
corresponding to WT and KO alleles are indicated to the right of each gel. (B) MEFs were 
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pretreated with various doses of IFNβ and tested for Ifitm2 and Ifitm3 gene induction by qRT-
PCR. Ifitm2 expression was not detected in Ifitm2−/− and Ifitm-del MEFs, and Ifitm3 expression 
was not detected in Ifitm3−/− and Ifitm-del MEFs. Bars show the means and standard errors of the 
means from three independent experiments performed in duplicate. Means were compared 
between control and IFNβ-treated cells using a nonparametric one-way ANOVA with Dunn's 
multiple comparisons (*, P < 0.05; ***, P < 0.001; ****, P < 0.0001). (C) MEFs were pretreated 
with the indicated doses of IFNβ and tested for Ifitm3 expression by quantitative Western 
blotting. (Left) Means from three independent experiments were compared between control and 
IFNβ-treated cells using a nonparametric one-way ANOVA with Dunn's multiple comparisons 
(*, P < 0.05). (Right) A representative Western blot with loading controls (β-actin) is shown. (D 
to H) The indicated MEFs were pretreated with 1 U/ml of IFNβ and subsequently infected with 
CHIKV 181/25 or CHIKV-LR at an MOI of 5. (D) At 14 h postinfection, MEFs were stained for 
viral E2 protein and analyzed by flow cytometry. (E and F) Cumulative flow cytometry data for 
CHIKV 181/25 and CHIKV-LR. Bars show the means and standard errors of the means (SEM) 
from five independent experiments performed in quadruplicate or duplicate. Means were 
compared between WT and deficient cell lines using one-way ANOVA with Dunnett's multiple 
comparisons (*, P < 0.05; **,P < 0.01; ***, P < 0.001; ****, P < 0.0001). (G and H) Kinetics 
of CHIKV 181/25 and CHIKV-LR replication in IFNβ-pretreated WT,Ifitm3−/−, and Ifitm-
del MEFs infected at an MOI of 5. Supernatant was harvested at indicated time points, and virus 
titers were determined. Curves show the means and standard errors of the means from the pooled 
data of two or three independent experiments performed in triplicate. Means at each time point 
were compared between WT and knockout cell lines using two-way ANOVA with Dunnett's 
multiple comparisons (*, P < 0.05; **,P < 0.01; ***, P < 0.001; ****, P < 0.0001).	  
	  	   84	  
Figure 3.2 
     
 Figure 3.2. Infection of other alphaviruses is enhanced in cells lacking Ifitm3 expression. 
WT, Ifitm3−/−, and Ifitm-del MEFs were pretreated with the indicated concentrations of IFNβ and 
subsequently infected with SFV (A), ONNV (B), VEEV-TC83 (C), or SINV (D) at an MOI of 5. 
At 14 h postinfection, MEFs were stained for viral E2 proteins and analyzed by flow cytometry. 
Bars represent the means and standard errors of the means from three independent experiments 
performed in duplicate. For each concentration of IFNβ, means between WT and knockout cells 
were compared using one-way ANOVA with Dunnett's multiple comparisons (*, P < 0.05; 
**, P < 0.01; ***, P < 0.001).  
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Figure 3.3	  
	  	   86	  
Figure 3.3. Ectopic expression of IFITM3 inhibits CHIKV infection. c-Myc-tagged firefly 
luciferase and Ifitm3 were cloned into the pFCIV vector and introduced into WT, Ifitm3−/−, 
and Ifitm-del MEFs via lentiviral transduction. (A and B) Successful transduction was 
determined by staining for c-Myc tag by flow cytometry (gray-filled are negative control; black 
lines, anti-c-Myc) (A) and Western blotting for firefly luciferase (detected with anti-c-Myc 
antibody) and Ifitm3 (detected with anti-Ifitm3 antibody) in transcomplemented MEFs (B). β-
Actin loading controls are provided below each gel. Results are representative of three 
independent experiments. (C) Flow cytometry contour plots of CHIKV infection in 
transcomplemented MEFs. Cells were infected for 6 h in the absence of IFNβ with CHIKV 
181/25 at an MOI of 5. Infection was determined by flow cytometry of E2-positive cells. (D) 
Pooled data from CHIKV infection. Bars represent the means and standard errors of the means 
from three independent experiments done in triplicate. Means were compared by Student's t test 
(**, P < 0.01).  
	  	   87	  
Figure 3.4 
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Figure 3.4. Role of Ifitm3 in restricting CHIKV binding, entry, and pH-dependent fusion. 
(A) CHIKV-LR was bound to firefly luciferase or Ifitm3-transcomplemented MEFs for 1 h on 
ice. After repeated rinses with chilled PBS, total RNA was isolated and analyzed for CHIKV 
RNA by qRT-PCR. Pooled data from 3 independent experiments done in duplicate are shown. 
(B) After CHIKV-LR binding and washing, MEFs were incubated at 37°C for 1 h to allow for 
virus internalization. MEFs were then treated with proteinase K on ice for 1 h to digest any 
bound but not internalized virions, followed by washing, RNA extraction, and analysis by qRT-
PCR. Data are representative of three independent experiments performed in duplicate. (C) As a 
control, we confirmed the efficiency of proteinase K for removing surface-bound (at 4°C) but not 
internalized CHIKV. MEFs treated with proteinase K had lower levels of CHIKV RNA as 
detected by qRT-PCR (higher threshold cycle [CT] values, P < 0.0001). (D and E) FFWO assay 
of CHIKV 181/25 on transcomplemented MEFs. CHIKV (MOI of 100) was bound to cells on ice 
for 2 h, followed by treatment with neutral (pH 7.4) or acidic (pH 5.5) medium at 37°C for 2 min 
to induce fusion. Medium was replaced with neutral culture medium supplemented with NH4Cl 
and incubated at 37°C for 14 h before analysis of CHIKV antigen-positive cells by flow 
cytometry. Data represent the means and standard errors of the means from three independent 
experiments done in triplicate. Means were compared by Student's t test (***, P < 0.001; 
****, P < 0.0001). 
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Figure 3.5 
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Figure 3.5.  Ifitm3 restricts CHIKV pathogenesis in vivo. Four-week-old WT 
and Ifitm3−/− mice were inoculated with 103 FFU of CHIKV-LR in the left footpad. (A) Viral 
titers in the ipsilateral ankle at days 3 and 7 postinfection. Data were pooled from two 
independent experiments, and each point represents one mouse (n = 8 to 10). The dotted line 
represents the limit of detection. No statistical difference was seen by the Mann-Whitney test. (B 
and C) Swelling of the ipsilateral ankle of infected WT and Ifitm3−/− mice at days 3 and 7 
postinfection. Area was determined by measuring the width and height of the ankle using digital 
calipers. Data are pooled from two independent experiments and are normalized to the measured 
area of the ankles just prior to infection. Each dot represents one mouse (n = 8 to 10). Asterisks 
indicate statistical differences by the Mann-Whitney test (**, P< 0.01; ***, P < 0.001). (D to K) 
Four-week-old WT and Ifitm3−/− mice were inoculated with 103 FFU of CHIKV-LR in the left 
footpad. Viral burdens in the serum (D), spleen (E), ankles (F and G), muscles (H and I), and 
wrists (J and K) at days 1 and 2 postinfection were determined by focus-forming assay. Dotted 
lines represent the limit of detection. Data are pooled from three independent experiments, and 
each dot represents one mouse (n = 13 to 16). Asterisks indicate statistical differences by the 
Mann-Whitney test (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001). 
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Figure 3.6 
A 
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Figure 3.6. Infection of splenocyte subsets by CHIKV-LR in WT and Ifitm3−/− mice. 
Splenocytes from 4-week-old WT and Ifitm3−/− mice were harvested 1 day after infection 
(103 FFU in the footpad); stained for neutrophils, inflammatory monocytes, dendritic cells, 
eosinophils, macrophages, and red pulp macrophages and for surface expression of CHIKV E1 
and E2 viral antigen; and analyzed by flow cytometry. (A) Detailed gating strategy for different 
cell subsets is shown. FSC, forward scatter; SSC, side scatter. (B) Representative contour plots 
of WT and Ifitm3−/− splenocytes gated for CHIKV antigen-positive cells, stained with either 
isotype control or anti-CHIKV envelope protein antibody. (C) Scatter plots indicate the number 
of CHIKV antigen-positive cells for each subpopulation. Data were pooled from two 
independent experiments. Each dot represents one mouse (n = 9 to 10). Asterisks determine 
statistical differences by the Mann-Whitney test (*, P < 0.05). Note the break in the y axis. (D) 
Viral kinetics of CHIKV-LR infection in bone marrow-derived WT and Ifitm3−/− macrophages 
infected at an MOI of 0.1. Data are pooled from five independent experiments performed in 
triplicate, and each point indicates mean and standard error of the mean. The dotted line indicates 
the limit of detection. Asterisks determine statistical differences by two-way ANOVA and 
Sidak's multiple comparisons (**, P < 0.01). hpi, hours postinfection. 
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Figure 3.7	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Figure 3.7. Ifitm3 protects against VEEV pathogenesis. (A and B) Four-week-old WT 
and Ifitm3−/− mice were infected with 106 FFU of VEEV-TC83-A3G in the footpad and followed 
for survival (A) and morbidity by weight loss (B). Data are pooled from two independent 
experiments (n = 19 to 21). Asterisks denote statistical differences by log rank test (***, P < 
0.001). (C) VEEV viral burden of serum, spleen, liver, inguinal lymph nodes (iLN), popliteal 
lymph nodes (pLN), brain, and spinal cord at days 1, 2, and 4 after infection of WT 
and Ifitm3−/− mice. Data are pooled from four independent experiments, where each dot 
represents one mouse (n = 6 to 10). Dotted lines represent the limit of detection. Asterisks 
indicate statistical differences by the Mann-Whitney test (*, P < 0.05; **, P < 0.01).  
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Table 3.1: Cytokine levels in joint tissue homogenates after CHIKV infection 
 Day +1 Day +2 
Cytokine Genotype pg/ml P pg/ml P 
IL-1α WT 7.6 (± 1.0) 0.2 9.8 (± 0.6) 0.03 
 Ifitm3-/- 12 (± 2.4)   14 ± 1.5)    
IL-1β WT 52 (± 11) 0.3 144 (± 18) 0.2 
 Ifitm3-/- 71 (± 14)   181 (± 9.2)   
IL-2 WT 11 (± 1.9) 0.03 15 (± 1.9) 0.09 
 Ifitm3-/- 16 (± 1.8)   21 (± 3.1)   
IL-3 WT 0.33 (± 0.06) 0.9 0.39 (± 0.08) 0.006 
 Ifitm3-/- 0.33 (± 0.06)   0.76 (± 0.06)   
IL-4 WT 3.2 (± 0.2) 0.3 4.2 (± 0.5) 0.1 
 Ifitm3-/- 3.2 (± 0.5)   6.1 (± 1.0)   
IL-5 WT 0.6 (± 0.2) 0.9 3.0 (± 1.0) 0.7 
 Ifitm3-/- 0.8 (± 0.4)   3.4 (± 1.0)   
IL-6 WT 1.5 (± 0.4) 0.8 8.8 (± 1.1) 0.4 
 Ifitm3-/- 1.9 (± 1.0)   11 (± 1.9)   
IL-9 WT 22 (± 7.1) 0.9 31 (± 9.1) 0.006 
 Ifitm3-/- 28 (± 16)   107 (± 24)   
IL-10 WT 1.1 (± 0.06) 0.3 3.1 (± 0.9) 0.02 
 Ifitm3-/- 1.3 (± 0.2)   5.3 (± 0.8)   
IL-12 (p40) WT 1.1 (± 0.2) 0.8 10 (± 1.6) 0.02 
 Ifitm3-/- 1.4 (± 0.3)   15 (± 0.8)   
IL-12 (p70) WT 2.8 (± 0.2) 0.1 6.2 (± 0.7) 0.5 
 Ifitm3-/- 3.8 (± 0.5)   7.0 (± 0.6)   
IL-13 WT LOD (38.7) 0.9 LOD  (38.7) 0.9 
 Ifitm3-/- 44 (± 5.7)   39 (± 0.8)    
IL-17 WT 0.3 (± 0.09) 0.9 0.3 (± 0.08) 0.8 
 Ifitm3-/- 0.3 (± 0.1)   0.2 (± 0.06)   
Eotaxin WT 151 (± 3.8) 0.5 176 (± 11) 0.9 
 Ifitm3-/- 162 (± 8.2)   176 (± 12)   
G-CSF WT 0.7 (± 0.1) 0.9 4.2 (± 1.2) 0.007 
 Ifitm3-/- 0.9 (± 0.3)   8.5 (± 0.8)   
GM-CSF WT 43 (± 4.9) 0.14 59 (± 6.4) 0.04 
 Ifitm3-/- 55 (± 5.0)   77 (± 5.7)   
IFN-γ WT LOD (1.2) >0.9 1.8 (± 0.3) 0.7 
 Ifitm3-/- LOD (1.2)   1.5 (± 0.14)   
KC WT 16 (± 2.6) 0.6 81 (± 15) 0.8 
 Ifitm3-/- 23 (± 5.6)   83 (± 13)   
MCP-1 WT 52 (± 15) 0.01 706 (± 119) 0.4 
 Ifitm3-/- 118.5 (± 25.44)   833 (± 70)   
MIP-1a WT 38 (± 1.4) 0.3 168 (± 29) 0.8 
 Ifitm3-/- 50 (± 7.8)   151 (± 13)   
MIP-1b WT 20 (± 3.9) 0.3 150 (± 33) 0.2 
 Ifitm3-/- 34 (± 8.5)   89 (± 23)   
RANTES WT 13 (± 2.4) 0.8 109 (± 28) 0.8 
 Ifitm3-/- 12 (± 3.1)   88 (± 24)   
TNF-α WT 17 (± 3.0) 0.004 48 (± 7.5) 0.5 
 Ifitm3-/- 41 (± 6.4)   56 (± 7.4)   
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Table 3.1. Mice were infected with 103 FFU of CHIKV-LR in the footpad. Ipsilateral joint 
tissues were collected at 1 and 2 days after infection, homogenates were prepared, and the 
indicated cytokines were measured by Bio-Plex array. Data represent the mean (± SEM) in pg/ml 
of 9 to 11 mice per group. Statistical significance was determined by the Mann-Whitney test. 
LOD indicates the limit of detection. 
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Chapter 4: Conclusions and Future Directions 
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CONCLUSIONS 
This study attempted to identify novel antiviral ISGs using a high-throughput, gene 
knockdown system in vitro. Compared to screens where candidate ISGs was expressed 
ectopically, this shRNA based system would allow for the characterization of targets in the 
context of a physiological antiviral state. In addition, by testing with an attenuated virus strain 
and a virus not extensively studied in this context, we hoped to increase the chances of 
discovering ISGs with milder, or virus family specific functions. Unfortunately, though the 
initial premise of the screen was sound, the commercial shRNAs were not previously validated, 
and only 1 of every 3 shRNAs against a target were guaranteed to have a significant knockdown. 
In fact, for the top ranked ISGs in the screen, very few had multiple shRNAs with a Z-score 
higher than the cutoff of 1.5. This suggested that the library was mostly composed of ineffective 
shRNAs, or were allowing for other off-target effects and thus compromising the results of the 
screen, reducing our confidence in the overall results. Independent assessment of ISGs using 
CRISPR is still in progress, and generation of validated clonal lines must be done to optimize 
this system.  
Of the top hits, we also had access to knockout mice for four of these ISGs: Ifitm3, Ifit2, 
Lamp3 and β2m. Using MEFs obtained from these mice, initial studies revealed that only Ifitm3 
had a potent antiviral phenotype against alphaviruses, a family that was previously considered in 
the literature to be in fact resistant to this ISG. Ifitm3 mediated restriction was not limited to the 
attenuated strain CHIKV-181/25, but also reduced viral replication of the pathogenic CHIKV-LR 
strain, as well as other arthritogenic and encephalitic alphaviruses in vitro. Mechanistically, 
Ifitm3 did not affect CHIKV binding or entry, but restricted fusion with the plasma membrane 
under conditions of ectopic expression. Ifitm3 proved to be important in vivo, as the lack of this 
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ISG allowed for an increase in the early viral burden in CHIKV infected mice, an increase in foot 
swelling at days 3 and 7 post infection, and an increase in the viral antigen load in splenic 
macrophages. By growth curves, Ifitm3 restricts viral growth in bone marrow derived 
macrophages at basal conditions, and may therefore act as a reservoir in vivo. The absence of 
Ifitm3 also promoted increased mortality in mice infected with the encephalitic alphavirus 
VEEV-TC83-A3G, likely due to early increased viral burden and spread. 
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FUTURE DIRECTIONS 
Screening for novel antiviral ISGs 
Assuming that the initial shRNA screen is still worth following up on, it is necessary to 
continue developing clonal CRISPR knockout lines. The bulk CRISPR lines failed due to the 
genetic heterogeneity of the cells. Even partial expression of a target ISG could be sufficient to 
lose a potential protective phenotype. As we observed in the Ifitm3 bulk CRISPR set, no 
variation of IFN or MOI tested could show a difference in restriction compared to scrambled 
negative controls, even though all the cell lines were selected for puromycin resistance. Western 
blot analysis revealed that Ifitm3 protein was still being produced, especially after IFN treatment, 
and was clearly sufficient to restrict CHIKV. Furthermore, validated clonal lines should be 
developed in other permissive cells to confirm that any phenotypes are ISG specific, and not due 
to an artifact of the cell line. A more prudent approach would be to consider restarting the screen 
with a more reliable means of targeted knockdown or knockout. Whether by CRISPR, CRISPRi, 
or by shRNA, the reduction of gene expression should be validated at least at the mRNA level by 
qPCR. The generation of such a library will take a lot of time to properly generate, and would 
ideally be done commercially or through a core service. 
ISG targets should be further tested across multiple primary and stable cell lines for their 
role in cell viability, basal transcription and cell cycle activity, to make sure these genes are not 
essential for survival. Following this, target ISGs should be re-introduced by ectopic expression 
to verify that viral restriction can be restored. Finally, relevance in vivo using knockout mouse 
models and studies to determine the stages and mechanism of viral restriction can proceed. 
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Characterizing Ifitm3 as an antiviral ISG 
There are many questions left unanswered concerning the role of Ifitms in the context of 
alphavirus pathogenesis. In our in vitro studies, we noticed that Ifitm-del locus knockout MEFs 
was more susceptible against viral infection than Ifitm3-/- MEFs. This suggests that the other 
Ifitms could also be involved in alphavirus restriction. While Ifitm2-/- MEFs were just as 
sensitive to CHIKV as WT MEFs, the protective role of Ifitm1 and the other non-IFN stimulated 
Ifitms absent in the locus deletion is currently unknown. Ifitm1-/- and Ifitm2-/- mice have recently 
been backcrossed to the C57BL/6J background and are available for further in vivo studies. 
C57BL/6J backcrossed Ifitm-del mice tend to die at birth, which unfortunately makes in vivo 
experiments difficult. However, Ifitm-del MEFs can be used for in vitro studies. This line can be 
complemented to ectopically express single Ifitms or different combinations of Ifitm genes, and 
subsequently infect with CHIKV to look for differences in growth kinetics and replication. 
Identification of other individual or a combination of antiviral Ifitms can be followed up by 
generating and infecting new Ifitm knockout mice to determine in vivo relevance. 
One of the most interesting phenotypes observed in the Ifitm3-/- mouse was the rapid 
early viral titers in the spleen, ipsilateral foot and serum. This led to the finding that splenic 
macrophages were more antigen positive in these mice compared to WT controls. However, we 
did not study the role of Ifitm3 in stromal cells. CHIKV is known to infect muscle cells, 
osteoblasts, and fibroblasts, all of which express Ifitm3. Since the titers at the joints were either 
comparative or only slightly higher at all timepoints examined, we opted to not look too much 
further into these tissues. To better understand the role Ifitm3 plays in restricting CHIKV 
pathogenesis of stromal cells in vivo, we can take advantage of a newly established technique in 
the lab called In Situ Hybridization (ISH). With this staining protocol, we can determine 
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histologically how CHIKV spreads from the site of infection to the stromal and hematopoietic 
cells by staining for viral RNA. Combined with H&E staining, and immunofluorescence staining 
of known cells susceptible to CHIKV, ISH can help us better understand the early kinetics of 
viral spread and the possible changes in viral tropism in the stromal cells of the infected ankle 
joints, and may better inform us as to why we see early higher viremia and titers in the spleen of 
knockout mice. As our earliest virological titers were done at 1 day post infection, these studies 
should include shorter timepoints, starting at 4 hours post infection.  
The role of Ifitm3 in later stages of infection is a further point of interest. For example, 
CHIKV and other alphaviruses egress from host cells by budding, and may incorporate Ifitm3 as 
part of their viral envelope, as has been observed with HIV-1 (72). If integration of Ifitm3 to the 
alphavirus envelope can be confirmed, subsequent studies into the downstream effects of 
infectivity can be considered. In particular, does the integration of Ifitm3 affect the ability of the 
virion to fuse with the endosomal membrane of host cells? Does this allow for faster viral 
clearance in the serum and tissues? Furthermore, it would be interesting to note if the absence of 
Ifitm3 results in a greater or more sustained viral burden at late or chronic stages of infection.  
As the mechanism of Ifitm3 mediated restriction is still unclear, it would be beneficial to 
have an alphavirus strain that has adapted to no longer be sensitive to this ISG. Serial passages of 
CHIKV either in Ifitm3-/- mice or MEFs should produce resistant variants. Genomic and 
structural comparisons of Ifitm3 sensitive and insensitive strains can help us better understand 
how Ifitm3 blocks endosomal viral fusion. An Ifitm3 insensitive strain may also be useful in 
understanding if this ISG has any role in promoting or preventing chronic infection. In the case 
of HIV-1, it has been observed that while the founder population is resistant to IFITM function, 
subsequent generations become more sensitive to IFITM3 as more mutations to escape 
	  	   104	  
neutralizing antibodies are made (73, 75, 123). A similar situation can be occurring in the case of 
CHIKV infection, where IFITM3 insensitive variants are responsible for maintaining a chronic 
phenotype. 
The IFITM3 human polymorphism rs-12252 results in a 21 amino acid deletion of the N-
terminus, which prevents localization to the endosomes. While this polymorphism was initially 
shown to alter sensitivity to IAV infections, subsequent studies have brought this observation 
into question (80–82). Recently however, an investigation into Hantaan virus suggests that the 
rs-12252 polymorphism is associated with greater disease severity and viral load (83). Thus, 
further studies on the importance and relevance of IFITM3 polymorphisms in the context of 
CHIKV and other viruses needs to be done. Understanding how different polymorphisms of 
IFITM3 do or do not affect restriction of viruses can be insightful towards deciphering the 
mechanism of this ISG. 
Finally, it would be interesting to note the in vivo importance of Ifitms and in particular 
Ifitm3 in the context of other alphaviruses. Our studies only looked at CHIKV pathogenesis and 
only touched on VEEV pathogenesis in vivo. Further investigations into the role of Ifitm3 in vivo 
against other arthritogenic and encephalitic alphaviruses will help clarify the differences in 
pathogenesis and viral tropism. For example, Mayaro and Ross River are both arthritogenic 
alphaviruses that induce a different swelling response compared to CHIKV (unpublished 
observations, Diamond Lab). The absence of Ifitm3 can theoretically allow for amplification of 
the viral kinetics and pathogenesis of these infections. It may even be possible that there are 
alphaviruses that are in fact not restricted by Ifitm3 in vivo. Preliminary day 1 post infection 
analysis with Mayaro suggested that there is no difference in titer in the spleen, serum or joints 
(unpublished observations). The identification of natural resistant alphavirus would be beneficial 
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in deciphering the mechanism of Ifitm3 restriction, and also identifying possible viral 
mechanisms of bypass or escape.  
As a point of interest, an investigation into the role of Ifitm3 restricting LACV infection 
in vivo should be initiated. If the published in vitro data is valid and orthobunyaviruses are 
restricted by Ifitm3, we can expect a survival difference in Ifitm3-/- vs WT mice. As we have 
shown, Ifitm3 is protective against encephalitic alphaviruses, however the virus strain of VEEV 
used is resistant to the antiviral mechanism of Ifit1. LACV however is not affected by Ifit1 (51), 
theroretically making it a better pathogen to use in understanding how Ifitm3 protects the CNS.  
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  of	  novel	  murine	  antiviral	  interferon-­‐stimulated	  genes	  against	  
alphavirus	  infection.	  
o Employed	  an	  shRNA	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  to	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  for	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  interferon-­‐stimulated	  genes	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chikungunya	  virus	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  flow	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  protective	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  interferon-­‐stimulated	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virus	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  culture	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  models	  of	  infection.	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  the	  role	  of	  immune	  cell	  subsets	  in	  pregnancy	  and	  testicular	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  upon	  Zika	  virus	  
infection.	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  Institutes	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  Viral	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   2007-­‐2009	  
Postbaccalaureate	  Research	  Fellow	  (IRTA)	  –	  Ted	  Pierson	  Lab	  
• Studied	  the	  pH	  dependent	  mechanisms	  of	  West	  Nile	  virus	  entry	  from	  host	  cells.	  
o Tested	  the	  hypothesis	  that	  flavivirus	  pH	  dependent	  fusion	  is	  directed	  by	  histidine	  
residues	  of	  the	  envelope	  protein.	  
o Generated	  a	  series	  of	  WNV	  mutations	  lacking	  one	  or	  more	  histidine	  residues	  on	  the	  
envelope	  protein	  using	  QuikChange	  mutagenesis.	  
o Characterized	  the	  viability	  and	  pH	  sensitivity	  of	  each	  mutant.	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  of	  California	  at	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  Department	  of	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   2003-­‐2007	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  –	  Krishna	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  Characterizing	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  genes	  for	  LOR3	  and	  NSY	  in	  Chlamydomonas	  reindardtii.	  
o Mutagenized	  wild	  type	  Chlamydomonas	  using	  UV	  radiation,	  and	  screened	  for	  
carotenoid	  deficiencies	  using	  HPLC	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LAB	  RELATED	  SKILLS	  
	  
Tissue	  culture:	   	   Growth	  and	  maintenance	  of	  primary	  and	  immortalized	  cell	  lines.	  	   	  
	   	   	   Experience	  with	  both	  mammalian	  and	  insect	  derived	  cells.	  
	  
Molecular	  biology:	   DNA	  and	  RNA	  isolation	  from	  cell	  lines	  and	  tissue.	  	   	   	   	  
	   	   	   PCR	  and	  qRT-­‐PCR.	  	   	   	   	   	   	   	   	  
	   	   	   Mutagenesis	  and	  cloning	  of	  plasmids	  using	  QuikChange,	  Gateway	  or	  restriction	  
enzyme	  digestion.	  	  
Transfection	  and	  transduction	  of	  cell	  lines.	  DNA	  sequencing	  and	  analysis.	  	  
Knockdown	  and	  knockout	  of	  target	  genes	  involving	  shRNA,	  siRNA	  and	  CRISPR.	  	  
Gel	  electrophoresis	  and	  Western	  blots.	  
	  
Immunological-­‐based:	   ELISA	  and	  ELISPOT.	  	  
Flow	  cytometry	  of	  cell	  lines,	  mouse	  organs	  and	  PBMCs.	  	  
Production	  and	  maintenance	  of	  bone	  marrow	  derived	  primary	  macrophages.	  	  
Cytokine	  assays	  from	  tissues	  and	  serum.	  
	  
Virology:	   	   Production	  and	  maintenance	  of	  virus.	  	  
Quantification	  of	  virus	  using	  qRT-­‐PCR,	  flow	  cytometry	  or	  focus	  forming	  assay.	  	  
Analysis	  of	  viral	  infectivity	  via	  growth	  curves.	  	  	  
Analysis	  of	  virus	  binding,	  entry,	  transcription	  and	  egress.	  
	  
In	  vivo:	  	   	   General	  mouse	  handling.	  	  
Experience	  in	  ip,	  tail	  vein,	  and	  sc	  injections.	  	  
Isolation	  and	  preparation	  of	  tissue	  and	  organ	  samples	  for	  microscopy,	  flow	  
cytometry,	  virological	  analysis,	  or	  histology.	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